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ABSTRACT
The impact of tumor associated stromal cells in tumor formation,
progression, and response to therapy has led to a paradigm shift in cancer
therapy. For many years, tumors were considered as a mass consisting only of
actively proliferating cancer cells and therapies were design to target these cells.
However, research in the last two decades has shown that tumors are not only
comprised of a heterogeneous population of neoplastic cells, but they are also
comprised of and infiltrated by a heterogeneous population of non-tumor cells
that contribute to tumor progression and potentially affect the efficacy of tumordirected chemotherapies. Tumors are now considered as complex organ
consisting of both cancerous and noncancerous cells interacting with each other
within the tumor microenvironment to promote malignancy.
For decades, 5- fluorouracil (5-FU), an inhibitor of the enzyme thymidylate
synthase (TS), has been used in the clinical management of colorectal cancer.
Although it has been beneficial to some patients, its use has been severely
limited by cytotoxic side effects due to its lack of specificity, affecting both rapidly
proliferating cancer and healthy normal cells, and acquired resistance by cancer
cells over time. To circumvent these limitations, we propose that genetic
modulation of non-tumor or stromal cells in the microenvironment might enhance
drug efficacy and reduce drug-induced cytotoxicity.
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Genetic modulation of stromal cells may be accomplished by utilizing
ribonucleic acid interference (RNAi) technologies. With RNAi, we were able to
suppress intracellular protein levels of TS prior to therapy and chemo-sensitized
cells to TS inhibitors. In vivo, we found that the use of constitutive H1 promoter
RNAi vector systems to sensitize hematopoietic stem cells in ApcMin/+ mice, was
problematic and toxic. However, using a mCMV constitutive RNAi vector which
was not toxic in an in vivo model system, we found that we can sensitize stromal
cells to the cytotoxic effects of 5-FU. To specifically direct chemo-sensitivity to 5FU to cells in the tumor microenvironment we utilized the promoter of
osteopontin, a gene that was only upregulated in hematopoietic cells in the tumor
microenvironment, to drive the expression of a TS silencing shRNA. This allowed
us to enhance chemo-sensitivity to 5-FU specifically within the tumor stroma.
In addition to enhancing the efficacy of TS inhibitors by modulating bone
marrow derived cells, we also targeted mast cells by incorporating a
pharmacological drug, Cromolyn that inhibits mast cells function, and combined
this with 5-FU therapy. We had previously found that mast cells are resistant to
5-FU and are recruited into the tumor microenvironment upon systemic treatment
of ApcMin/+ mice with 5-FU. We hypothesized that inhibition of mast cells in
combination with 5-FU treatment might enhance anti-tumor efficacy of 5-FU or
block the recurrence of tumors post-therapy. The results showed that
administration of Cromolyn after systemic treatment with 5-FU decreased
recurrence of tumor post therapy. These findings suggest that modulation of the
tumor stromal cells by genetic modification or by pharmacological methods have
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the potential to enhance the anti-tumor efficacy of TS inhibitors. It will be
necessary to assess the long-term effects and the mechanistic underpinnings of
these studies to realize their clinical utility.
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CHAPTER 1
INTRODUCTION
1.1 COLON CANCER
In 2014, the American Cancer Society estimated that approximately 136,830
individuals were diagnosed with colorectal cancer (CRC) and approximately
50,310 will die from this disease. CRC is the third most diagnosed and the
second cause of cancer related deaths in the United States. CRC begins with the
development of polyps in the colon or large intestines, with low incidents

Figure 1.1: Stages of Colorectal Cancer: Progression of polyp development into cancer
on the lining of the intestinal wall. (Johns Hopkins Cancer Center, Internet)

occurring in the small intestines. Studies have shown that the formation of polyps
normally occur in a period of ten to twenty years, during which a non-cancerous
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growth forms on the inner lining of the colon or the large intestine (Stryker, Wolff
et al. 1987; Winawer and Zauber 2002). These non-cancerous adenomatous
polyps are likely to become cancerous upon continuous growth, developing into
an adenocarcinoma, a malignant tumor of glandular cells (Figure 1.1). The
progression from adenomatous polyps to adenocarcinomas is the result of
mutations, which occur in tumor suppressor genes such as the adenomatous
polyposis coli (APC) and tumor protein p53 (TP53). Mutation of the APC gene
occurs in the early stage of CRC development, and is responsible for familial
adenomatous polyposis (FAP), an inherited form of CRC (Jasperson, Tuohy et
al. 2010). The APC gene encodes a multifunctional protein that regulates the
expression of β-catenin in the Wnt signaling pathway, cell adhesion, proliferation,
and apoptotic pathways (Coppede, Lopomo et al. 2014). Typically, the APC
protein forms a cytoplasmic complex with other proteins in the Wnt signaling
pathway. This complex targets β-catenin by ubiquitination for proteasome
degradation keeping its intracellular levels low. Conversely, loss of APC function
causes accumulation of β-catenin in the cytoplasm, and its translocation into the
nucleus where it assists in the activation of genes essential for cell proliferation,
resulting in abnormal growth and adenomatous polyps.
Mutations in TP53 typically occur after the APC mutation, as the polyp
continues to grow and become cancerous. TP53 is a nuclear protein that initiates
cell cycle arrest to initiate repair or apoptosis in response to DNA damage
(Vogelstein, Lane et al. 2000). Loss of TP53 function, which is critical for sensing
and repairing damaged DNA, allows cancerous cells to escape the cell cycle
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checkpoint and proceed with unregulated cell division to produce daughter cells
with mutated DNA. This mutation promotes the transition from an adenomatous
polyp to an adenocarcinoma.
Approximately 96% of colorectal cancers are adenocarcinomas (Stewart,
Wike et al. 2006). Common symptoms include bleeding from the rectum,
discomfort in the lower abdomen, constipation and diarrhea, and loss of appetite.
Fortunately, early screening via a colonoscopy allows visual examination of the
colon so that adenomas or adenocarcinomas can be excised from the colon and
large intestine. Although the advancement of colonoscopies has increased CRC
survival (Edwards, Ward et al. 2010), there is room for improvement to decrease
of CRC related deaths. To date, the 5-year survival rate is approximately 89.9%
for localized CRC, 70.5% when CRC spreads to regional lymph nodes, and
12.9% if CRC has metastasized to distant organs (Surveillance, Epidemiology,
and the End Results (SEER) Program). The majority of CRC related deaths
result from metastatic CRC cells entering into the lymph nodes and blood
vessels, and spreading to distant organs such as the liver and/or lungs. Current
treatments are not efficient in blocking this process. In addition, contributing to
the inadequacies of our anti-cancer treatments is the reoccurrence of the cancer
with more aggressive properties, or the development of resistance against
chemotherapy, such as 5-Fluorouracil (5-FU) that is commonly used to treat
CRC. Thus, in order to combat and eliminate this disease, it is important to
develop new anti-cancer therapies or utilize current anti-cancer therapies in
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combination with novel therapies to enhance their efficacy while minimizing their
toxicities.

1.2 HALLMARKS OF CANCER
In order develop effective anti-cancer therapies and to resolve the
problematic side effects resulting from their lack of specificity for cancer cells, it is
important to understand the complexity of cancer development. Currently, eight
properties define the hallmark of cancer cells. These properties provide a
framework for the development of novel therapies. These hallmark properties
include: sustaining proliferative signaling, evading growth suppressors, resisting
cell death, enabling replicative immortality, inducing angiogenesis, activating
invasion and metastasis, reprogramming of energy metabolism, and evading
immune destruction (Hanahan and Weinberg 2011). The unregulated production
of growth signals provides cancer cells the ability to acquire the hallmark of
sustained proliferative signaling. This causes an imbalance in homeostasis,
wherein cancer cells uncontrollably produce growth factors for themselves.
However, it is not sufficient for cancer cells sustain proliferation because cellular
checkpoints within cell division can inhibit the continuous growth necessary to
develop a tumor mass. Thus, obtaining the ability to evade the regulation of
growth suppressors, through mechanisms such as TP53 is necessary for tumor
progression. Growth suppressors negatively regulate cell proliferation contingent
on DNA abnormalities and the lack of normalcy due to stress caused by
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nucleotide, oxygen, and energy levels within or outside the cell. Mutations in
growth suppressors disrupt induced apoptosis.
Alternatively, the cancer cell’s quest for survival may also increase the
expression of anti-apoptotic regulators that contribute to resistance to apoptosis.
Under normal conditions, the balance of pro- and anti- apoptotic proteins
regulates programmed cell death. The abnormalities in cancer cells creates
imbalance in favor of inhibiting the trigger of death. Resisting cell death does not
guarantee cancer cells the ability for unlimited proliferation, but obtaining the
hallmark of immortality does. Immortality is achieved by up regulating the
expression of telomerase, an enzyme responsible for elongating telomeres,
resulting in extended protection of chromosomal DNA. With each cell division,
the telomere length decreases, until it reaches a point at which the cell goes into
a silencing phrase or program cell death. Hence, immortality ensures the tumors
capability to expand. However, as the tumor expands it must ensure the ability to
sustain a healthy environment to maintain its growth. Tumor progression requires
sources of energy, the import of nutrients, and the export of waste, which is
accomplished by increasing energy metabolism and inducing angiogenesis. The
newly discovered hallmark of reprogramming energy metabolism allows cancer
cells to survive by up regulating the transport of glucose into the cell where it is
broken down to generate energy and metabolites to compensate for the increase
in cell growth and division. Angiogenesis is the process of developing new blood
vessels from existing vessels that allow the import and export of the necessary
nutrients and waste. The ability to induce angiogenesis sustains the growth of the
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tumor in a localized region; however, the ability to travel to another organ
requires the activation of invasion and metastatic characteristics. Normally
aggressive cancers alter the expression of cell-to-cell adhesion molecules; giving
cancer cells the capacity to invade nearby blood vessels in an attempt to spread
to a distal organ. The accomplishment of metastasizing to a distal organ is
contingent on the cancer cell’s ability to detached from the primary tumor, survive
in circulation, extravagate and adapt to the microenvironment of the distal organ
to survive. Finally, the property of evading immune surveillance is a significant
hallmark that allows cancer cells to avoid destruction by the immune system,
which served to eliminate rogue cells. Delineation of these hallmark properties
has provided clarity to cancer development and its capability to resist therapies.
Cancer research has evolved from the perspective of exclusively targeting and
understanding the development of neoplastic cells, to the forefront of studying
the intricate relationship that develops between both neoplastic and nonneoplastic cells derived from bone marrow to create the tumor microenvironment
(TME).

1.3 TUMOR MICROENVIROMENT
Since the recognition of the TME, a paradigm shift in cancer therapy has
occurred, such that the tumor is perceived to be an organ or complex tissue
(Egeblad, Nakasone et al. 2010), composed of a heterogeneous populations of
both malignant and non-malignant cells and extracellular matrix, which function
abnormally to promote and sustain a pro-tumorigenic environment, i.e. the
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hallmarks of cancer (Coussens and Werb 2002; Chantrain, Feron et al. 2008;
Whiteside 2008; Hanna, Quick et al. 2009; Peddareddigari, Wang et al. 2010;
Hanahan and Coussens 2012). This heterogeneous population of non-malignant
cells within a tumor includes, but is not limited to the following cells: tumor
associated macrophages (TAMs); myeloid derived suppressor cells (MDSCs),

Figure 1.2: Tumor Microenvironment: Infiltration of bone marrow derived cells into
the tumor microenvironment (TME). The tumor stroma is comprised of many immune
cells that influence the tumor response to anti-cancer therapies.

mast cells, and cancer associate fibroblasts (CAFs), monocytes, endothelial
cells, and neutrophils (Figure 1.2).The TME has the potential to activate TAMs
into two subgroups: M1 (anti-tumor) or M2 (pro-tumor) macrophages (Gordon

7

2003; Mantovani, Sica et al. 2007). MDSCs have been shown to cooperate in the
non-responsiveness

of

T-cells

to

promote

tumorigenesis

(Nagaraj

and

Gabrilovich 2008). Mast cells exhibit the ability to secrete many pro-tumorigenic
growth stimulatory factors, which can trigger the angiogenic switch to turn on
angiogenesis (Coussens, Raymond et al. 1999). In response to tumor growth,
CAFs are secrete a host of growth factors such as the epidermal growth factor
(EGF), transforming growth factor beta (TGF-β), and hepatocyte growth factor
(HGF) (Kalluri and Zeisberg 2006). These non-cancerous cells provide a proinflammatory environment by secreting cytokines, chemokines, and growth
factors essential for the initiation and maintenance of tumor growth. In addition to
the infiltration of these heterogeneous population of cells within the tumor, the
composition of the extracellular matrix, for example, laminin, collagen,
fibronectin, and proteoglycans can promote tumor progression (Peddareddigari,
Wang et al. 2010) and provide resistance to drug therapies due to abnormal
tissue organization that provides a hindrance to drug delivery (Egeblad,
Nakasone et al. 2010). For example, type 1collagen plays a significant role in
regulating tumor sensitivity to various anti-neoplastic therapies (Loeffler, Kruger
et al. 2006).
These examples represent minuscule information on the intricate
relationship between cancer and non-cancerous cells. These studies confirm that
the neoplastic cells are not solely acting alone, but they collaborate and coevolve with various immune cells to orchestrate tumor growth and development.
These tumorigenic properties increase as the tumor matures causing
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morphological changes to occur within the TME to become supportive. Hence
advanced stages of cancer exhibit altered tumorigenic properties in comparison
to the early stages of cancer. The roles of these immune cells need intense
investigation, to have a better understanding of the supportive role of the TME at
the different stages of tumor development. In addition, this will contribute to the
knowledge of how the TME provides protection against chemotherapies,
providing insight into the development of more effective ways to target the tumor.

1.4 THE ROLE OF MAST CELLS IN TUMOR BIOLOGY
As previously described, the TME consists of bone marrow derived cells
that contribute to tumor formation and potentially play a vital role in resistance to
current chemotherapies. In particular, there is a growing interest in the role of
mast cells in cancer development, and recent studies have identified functions of
these cells in tumor biology. Historically, mast cells are typically associated with
immunoglobulin E (IgE)-mediated response to an allergic reaction or an
asthmatic incident. The IgE mediated response causes the activation of mast cell
degranulation, which results in the crosslinking of antigens and IgE molecules
that are bound to the high affinity receptors, FC epsilon RI (FcεRI) located on the
cell surface of mast cells (Gould, Sutton et al. 2003). This immune response
provokes inflammation resulting in recruitment and activation of additional
immune cells to the local site. Thus, mast cells are effectors cells that exert
immune signals to regulate and recruit other immune cells. These granulocytes
cells are subdivided into two subgroups; mucosal and connective mast cells. The
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differences between the subgroups is dependent the content of granules, which
occurs during maturation. Mast cell precursors are released from the bone
marrow as immature cells and migrate into various tissues within the body to
undergo maturation and differentiation. Maturation and differentiation influenced
by the infiltrated tissue environment resulting in a heterogeneous population of
mast cells throughout the body. Mast cell granules have three subgroups: preformed granules, de novo synthesized granules, and cytokines and chemokines.
The pre-formed granules include histamine, heparin, and the proteases tryptase,
chymase, and carboxypeptidase A3 (CPA3). The second group is the de novo
synthesized lipid mediators, which includes: LTC4 and PGD2, and

the third

category consists of the various cytokines and chemokines, such as but not
limited to tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor
(VEGF), fibroblast growth factor (FGF), and matrix metallopeptidase-9 (MMP9)
(Theoharides, Kempuraj et al. 2007). Upon degranulation, the pre-formed
granule mediators are immediately release within minutes; while the de novo
synthesized mediators are released slowly within a period of three to twelve
hours later. In addition, the mechanism for releasing the mediators can occur by
either

complete

or

selective

degranulation

(Dvorak

and

Kissell

1991;

Theoharides and Kalogeromitros 2006). The role of mast cells in tumor formation
and immunity is poorly understood, and accumulating evidence has shown
controversial roles in tumor biology. Mast cells can either display anti-tumor or
pro-tumor responses depending on the type of cancer and the stage of the tumor
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development (Groot Kormelink, Abudukelimu et al. 2009; Ribatti 2013; Oldford
and Marshall 2014).
Mast cells have been shown to mediate anti-tumor response to cancer in
in vivo model systems. In ApcMin/+mice, a model of colon carcinogenesis, genetic
ablation of mast cells resulted in larger and increased number of intestinal tumors
compared to wild type littermates, suggesting that mast cells can suppress
intestinal tumor development (Sinnamon, Carter et al. 2008). In addition, several
studies suggest that IgE mediated activation of mast cells within tumor results in
an anti-tumor immune response (Jensen-Jarolim, Achatz et al. 2008; Teo, Utz et
al. 2012; Singer and Jensen-Jarolim 2014). Mast cells can also regulate the
activity of immune cells. For example, mast cells can promote recruitment of
MDSCs into the tumor and activate their expression of IL-17, which in turn
mobilizes and suppresses the pro-tumorigenic activity of T-regulatory cells within
the tumor. Collectively, these studies suggest that mast cells induce anti-tumor
responses and play a role in promoting inflammation to recruit additional
leukocytes into the tumor region where they activate or regulate immune cell
activity and induce cytotoxic activity.
Alternatively, mast cells can display a pro-tumorigenic response. Studies
have shown that pro-inflammatory mediators from mast cells can promote tumor
proliferation and provide a suitable environment to sustain tumor growth and
development. Gounaris and colleagues showed that mast cells for polyp
development in ApcMin/+mice (Gounaris, Erdman et al. 2007). In addition poor
prognosis has been correlated to high tumor infiltration of mast in many human
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cancers such as melanoma, lung, gastric, colorectal, and prostate carcinomas
(Groot Kormelink, Abudukelimu et al. 2009). An in vitro study utilizing the human
mast cell line, LAD2 demonstrated the capacity of mast cells to regulate the
invasiveness of cervical cancer cells, yet cervical cancer cells were able to
stimulate the degranulation of mast cells, suggesting an intimate communication
between tumor and inflammatory immune cells (Rudolph, Boza et al. 2008).
Another study using a HPV16 transgenic mouse model of squamous cell
epithelial carcinoma showed that chymase released from tumor infiltrating mast
cells activated MMP9 resulting in extracellular remodeling (Coussens, Raymond
et al. 1999). This study also demonstrated that mast cells infiltrated tumors prior
to the angiogenic switch. To validate the role of mast cells in angiogenesis and
tumor remodeling, another study using a Myc-induced pancreatic islet tumor
model showed infiltration of mast cells within twenty-four hours of Myc activation.
The recruitment of mast cells resulted in the expansion of Myc-induced tumors
(Soucek, Lawlor et al. 2007). Together, these studies show that mast cells
perform pro-tumorigenic roles by contributing to tumor remodeling, angiogenesis,
and immune suppression.
The pro-tumorigenic roles of mast cells affect the efficacy of anti-cancer
therapies by contributing to tumor progression and assisting in tumor remodeling
and tumor sustainability. Currently, the efficacy of anti-cancer therapies is
dependent on its direct deliverable contact with cancer cells within the tumor
where its cytotoxic action can destroy or reduce tumor burden. However, tumor
remodeling can inhibit delivery of anti-cancer therapies to promote relapse. It is
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important to decipher the pro-tumorigenic roles of mast cells to develop
strategies to enhance the efficacy of anti-cancer therapies.

1.5

THYMIDYLATE SYNTHASE AND ITS INHIBITOR 5-FU
Thymidylate synthase (TS) is an enzyme that catalyzes the reductive

methylation of 2’ deoxyuridine- 5’ monophosphate (dUMP) to 2’ deoxythymidine5’-monophosphate (dTMP) and dihydrofolate using 5,10-methylenetetrahydrofolate (CH2THF) as a methyl donor (Danenberg 1977; Carreras and Santi 1995).
Subsequently, dTMP is sequentially phosphorylated into 2’-deoxythimdine–
5’diphosphate (dTDP), and then into 2’ deoxythmidine- 5’ triphosphate (dTTP),
an essential component for DNA replication and repair in actively proliferating
cells. Importantly, this pathway provides the sole intracellular source of dTTP,
thus, TS has been an important target of chemotherapeutic agents. In addition to
its catalytic function, TS is an auto-regulatory protein that binds to its mRNA to
repress its translation and has been shown to interact with the mRNAs of TP53
and c-myc (Chu and Allegra 1996). TS inhibition results in depletion of dTMP and
accumulation of dUMP leading to increased levels of deoxyuridine triphosphate
(dUTP) that is mis-incorporated into DNA, resulting in DNA fragmentation and
ultimately cell apoptosis (Longley, Harkin et al. 2003; Garg, Henrich et al. 2010).
TS inhibitors are typically substrate analogs or analogs of the folate co-factor.
The most widely used TS inhibitor is the 5-FU, a fluoropyrimidine that has been
widely used in the clinical management of colon and head and neck cancers. 5FU is structurally similar to uracil; however, a fluorine atom replaces a hydrogen
atom at the C-5 position. After administration, 5-FU is transport into cells, where
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it is converted into the powerful TS inhibitor fluorodeoxyuridine monophosphate
(FdUMP). FdUMP has the same affinity to TS as dUMP: however, when bound to
TS, the fluorine atom at the 5’ position cannot be displaced, and it forms a stable
ternary complex with TS and 5,10-CH2THF resulting in TS inhibition. TS inhibitors
based on folate analogs include tomudex (raltitrexed), liposomal GW1843U89,
and capecitabine (Rose, Farrell et al. 2002).
Expression of TS after exposure to anti- therapy, such as 5-FU has shown to
increase proteins levels, a consequence of inhibiting TS activity, thus allowing
translation of the mRNA and production of the protein(Van der Wilt, Pinedo et al.
1992).
Although 5-FU has been used for many decades in the clinical management of
cancers, its use has been limited by drug induced toxicities and acquired
resistance by cancer cells. Cancer resistance to TS inhibitors can occur through
a number of mechanisms. TS can be over expressed in tumors due to gene
amplification or mutations that may cause resistance. TS auto-regulates its gene
expression, by binding to its mRNA. However, upon treatment with TS inhibitors,
bounded TS is released from its mRNA allowing its translation, which in turn
increases intracellular TS protein levels (Chu and Allegra 1996). The
effectiveness of 5-FU depends on the availability of 5,10-CH2THF. The active
metabolite, FdUMP forms an unstable binary complex with the enzyme, resulting
in poor inhibition. However, in the presence of 5,10-CH2THF stabilizes the
ternary complex inhibiting the catalytic function of the enzyme (Aherne,
Hardcastle et al. 1996). Thus, tumors expressing low levels of 5,10-CH2THF are
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resistant to 5-FU, however, addition of the drug Leucovorin (LV), increases
intracellular levels of 5,10-CH2THF resulting in enhanced sensitivity (Matherly,
Czajkowski et al. 1990). Another mechanism of resistance is the salvage
pathway which allows for the recovery of free bases, such as thymidine that are
byproducts of degrading DNA, to be recycled for nucleotide biosynthesis through
the action of the enzyme, thymidine kinase (Kinsella, Smith et al. 1997). The
salvage pathway can compensate for the lack of thymidylate production resulting
from TS inhibition.

Acquired resistance cancan also result from mutations in

TP53 wherein damaged DNA resulting from mis-incorporation of FdUTP is
unrecognized allowing cells to escape apoptosis (Ahnen, Feigl et al. 1998). On
the other hand, cancer cells with wild type TP53 can still be resistant to 5-FU
therapy by altering the regulation of the cell cycle. In the presence of 5-FU
resistant cells had increased tendency to arrest in G1 and G2 phases, allowing
DNA repair prior to replication; unlike the parental cell line that had a tendency to
arrest in the S phase (De Angelis, Svendsrud et al. 2006). In addition to acquired
resistance, 5-FU therapy is limited by drug induced toxicities associated with its
lack of specificity, targeting both actively dividing cancer as well as healthy
normal cells. Some side effects from 5-FU include alopecia, myelosuppression,
and mucositis. Considerable attempts have been made to enhance the
effectiveness of 5-FU, while lowering its toxic side effects. These include the
combination of 5-FU chemotherapy with targeted therapies. The impact of 5-FU
on stromal cells is only beginning to be explored. Targeting both the tumor and
tumor microenvironment might enhance our ability to kill colorectal cancer cells.
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We hypothesize that stromal cells are also direct targets of 5-FU and that their
chemo-sensitivity to 5-FU might determine tumor sensitivity to the therapy.
Targeting the microenvironment is genetic modification or pharmacological
inhibition of pro-tumorigenic activities of bone marrow derived cells infiltrating the
tumor microenvironment, might be viable strategies to enhance anti-cancer the
anticancer efficacy of 5-FU.

1.6 PARADIGM SHIFT IN ANTI-CANCER THERAPIES
Targeting both the tumor as well as the tumor stroma is a paradigm shift in
our approach to enhance the efficacy of anticancer therapies while enhancing
selectivity and minimizing toxicity and relapse. Clinical trials targeting the
extracellular matrix (ECM), endothelial cells and pericytes, fibroblasts, and innate
immune cells have shown progress in combating cancer (Joyce 2005), however,
these strategies are only beginning to be developed. The recognition of tumors
as a complex collection of cancer cells interacting and recruiting normal noncancerous cells has altered our perception of cancer development, which has
also alter how we must combat this disease. Traditionally, anti-cancer therapies
only targeted actively proliferating cancer cell by surgical removal of the tumor
mass that may be combined with radiation or chemotherapy, or a combination of
both. These treatments have only been moderately effective. Since the
establishment of

the critical role of the tumor microenvironment in cancer

initiation and progression, new anti-cancer therapies have emerged (Hanna,
Quick et al. 2009) that can be harnessed to enhance the efficacy of prominent
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existing chemotherapeutic drugs such as 5-FU. Furthermore, targeting stromal
cells might provide an opportunity to enhance the specificity of cancer
chemotherapies.

Thus, combining genetic modulation or pharmacologically

inhibition of bone marrow derived cells (BMDCs) within the TME with 5-FU
therapy may be beneficial in reducing drug toxicity or the occurrence of relapse.

1.7 GENETIC MODULATION OF BONE MARROW DERIVED
CELLS
The plasticity of BMDCs has the potential to constitute a pro-tumorigenic
microenvironment for cancer cells. A review by Chantrain proposes three
mechanisms by which bone marrow cells support the initiation and progression of
cancer:

first,

through

the

recruitment

of

cancer

cells

to

enrich

the

microenvironment, second, by infiltration into the tumor stoma to suppress
immune response, and third, by promoting the development of the pre-metastatic
niche (Chantrain, Feron et al. 2008). Numerous studies have demonstrated an
array of pro-tumorigenic responses from BMDCs infiltrating the into primary
tumor microenvironment permitting tumor growth (Egeblad, Ewald et al. 2008;
Roorda, ter Elst et al. 2009; Fowler, Mundy et al. 2012; Kidd, Spaeth et al. 2012;
Srivastava, Andersson et al. 2012; Zou, Zheng et al. 2012). Tumors have
suppressed immune responses to recruit and activate MDSCs, which have been
associated with malignancy and poor prognosis (Srivastava, Andersson et al.
2012). In addition, BMDCs can influence the development of the vasculature of
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the tumor tissue, hampering the administration and reducing the effects of
anticancer drugs (Mizukami, Sasajima et al. 2012). The ability of BMDC to
circumvent immune response and reduce efficacy of anti-neoplastic drugs is the
subject of ongoing investigation. It is important to understand the role of BMDCs
in tumor stoma to determine if genetic modulation of these cells can enhance
efficacy of antitumor drugs. Transplantation of genetically modificed BMDCs may
be used to alter gene expression in stromal cells to enhance tumor response to
pre-existing therapies. For example, the knockdown of the Wnt signaling inhibitor
Dickkopf1(DKK1) in bone marrow derive mesenchymal stem cells (MSCs)
repressed myeloma development in mice (Fowler, Mundy et al. 2012), and
MSCs engineered to express lymphotoxin induced tumor regression (Zou, Zheng
et al. 2012).

Genetic modification of BMDCs might be an effective tool to

enhance the efficacy of anti-neoplastic therapies since they can influence tumor
resonse to therapy by their ability to suppress immune responses.

1.8 PHARMACOLOGICAL INHIBITION OF BMDCs
An alternative to targeting the TME is by inhibiting the pro-tumorigenic
activities of BMDCs, such as mast cells, pharmacologically. Mast cells have been
shown to play critical roles in tumor initiation, progression, and response to
therapy. Thus, effective anti-cancer therapies may need to target mast cells in
addition to cancer cells. Several studies have used the pharmacological
stabilizer, sodium cromoglicate (Cromolyn), a drug known to inhibit mast cell
degranulation. Initially Cromolyn was used to treat acute inflammation which
occurs during an asthma attack (Altounyan 1975). However, recent studies have
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shown a reduction in tumor burden mice after administration of Cromolyn
(Gounaris, Erdman et al. 2007; Soucek, Lawlor et al. 2007). Based on these
results, we have considered the possibility that Cromolyn might play a synergistic
role in anti-cancer therapy. However, the mechanism by which Cromolyn inhibits
mast cells is not fully understood. It is thought to stiffen the cellular membrane,
which indirectly inhibits the influx of chloride into the cell that in turn inhibits the
ability of the cell ability to trigger.

1.9 EXPERIMENTAL MODELS
A. In-vitro cell model
Mus musculus thymidylate synthase (MusTS) was stably transfected into
a TS-deficient Chinese hamster lung (CHL) cell line RJK88.13 (Nussbaum,
Walmsley et al. 1985). Stable transfectants were selected in media lacking
thymidine in the presence of the nucleoside transport inhibitor dipyridamole.
Stably transfected cells were grown in mass culture. The CHL(MusTS) cell line
was used to target TS specifically to assess the sensitizing effects of diminished
TS expression in response to 5-FU therapy.

B. Transgenic mouse model
The C57BL/6J-ApcMin/+ mouse has been used as an in vivo model for the
initiation and progression of intestinal adenomas. These mice are heterozygous
for a mutant allele of the APC tumor suppressor gene, which genetically
predisposes them to the spontaneous development of adenomas within the
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intestinal tract (Moser, Pitot et al. 1990). Tumors develop in these mice at an
early stage due to the loss of the remaining wild-type APC allele, which leads to
insufficient expression of APC (Powell, Zilz et al. 1992; Su, Kinzler et al. 1992).
The APC mutation is similar to that the germline mutation found in the human
hereditary form of colorectal cancer, familial adenomatous polyposis (FAP)
(Levy, Smith et al. 1994). Although FAP accounts for less than 2% of colorectal
cancer incidence, mutations in the APC gene have accounted for 80% of
sporadic colon tumors (Kinzler and Vogelstein 1996). Most of the adenomas that
develop in these mice are located in the small intestines with a few developing in
the colon, while in humans tumors develop exclusively in the colon.
Nevertheless, the ApcMin/+mouse model is useful for understanding the initiation
of tumor development and progression, and is a useful tool for developing or
examining the effects of therapeutic agents in vivo.

C. Syngeneic mouse model
The transplantable syngeneic CT26 tumor model in Balb/c mice is another
model to examine the role of microenvironment in tumor response to 5-FU
therapy. CT26 colon adenocarcinoma cells are injected into the flank of Balb/c
mice where tumors are allowed to develop prior to therapy. CT26 cells were
generated in Balb/c by treatment with the carcinogen N-nitroso-N-methylurethane(NNMU) where they were isolated and to grow in vitro (Brattain, Strobel-Stevens

et al. 1980). The tumorigenic property of this cell line was sustained when
transplanted into Balb/c mice, thus providing the ability to assess tumor growth
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rates. By using this model, it allows for rapid tumor growth, which can be excised
to quantify BMDC infiltration and expression of mRNA levels within the tumor.
Thus, this syngeneic mouse model is practical for studying the response of
BMDCs after exposure to different combinations of chemotherapeutic agents.

1.10 REVIEW OF LITERATURE (GENETIC MODULATION OF
BMDCs)
A. BMDCs

infiltrate

the

intestinal

tumor microenvironment in

ApcMin/+mice.
In previous studies, Davis et al. showed that bone marrow can be
successfully

transplanted

and

engrafted

into

ApcMin/+ mice.

Prior

to

transplantation, the recipient ApcMin/+ mice were lethally irradiated with 950 rads
to deplete existing hematopoietic system.

Age matched donor marrow from

C57BL/6-UB1-eGFP mice expressing the enhanced green fluorescent protein
(eGFP) under the control of the human ubiquitin promoter was extracted from the
femur and tibia. The bone marrow is directly transplanted into recipient mice, or
grown in culture and fractionated to obtain hematopoietic stem cells (HSCs).
Transplantation of whole marrow or purified HSCs was performed by tail vein
injection. Full engraftment occurs within four to six weeks after transplantation.
Tissue sections were collected at eight weeks post transplantation to examine
the engraftment of donor eGFP bone marrow by confocal microscopy. The
results showed that donor derived eGFP marrow infiltrated both normal and
tumor regions of the small intestine and colon. Infiltration of the eGFP bone
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marrow was greater in tumor regions (75-80%) within the small intestines and
colon as compared to normal, non-tumor regions (10%) (Davis, Price et al.
2011). These results suggest that genetically modified bone marrow derived cells
transplanted into ApcMin/+ mice will successfully infiltrate the tumor regions of the
intestines and colon.

B. BMDCs expressing E. coli TS exhibits resistance to TS inhibitors.
Previous studies have demonstrated that the an Escherichia coli TS gene
whose codon usage has been optimized for expression in mammalian cells
(OPTecTS) can confer high levels of resistance to TS inhibitors (Fantz, Shaw et
al. 2000; Shaw, Berger et al. 2001). Shaw et al. optimized the E. coli TS gene by
introducing mutations in the cDNA resulting in stabilization of the protein in
mammalian cells. OPTecTS was cloned into a Harvey murine sarcoma-based
retroviral vector and stably transfected into a TS-deficient CHL cell line
(Nussbaum, Walmsley et al. 1985); wild type ecTS (wtecTS) and humanTS (hTS)
were used as controls. Stably transfected cells expressing OPTecTS and the
controls were treated with various concentrations of the TS inhibitor, raltitrexed
(RTX) in the presence of dipyridamole to determine the concentration that
inhibited the growth of fifty percent of the treated cells (IC50). The results showed
that cells transfected with OPTecTs were 11-fold more resistant to RTX than
cells expressing hTS while cells expressing wtecTS were slightly more resistant
compared to cells expressing hTS. In addition, result showed greater than 75%
and greater than 95% of bone marrow cells transduced with OPTecTS were
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resistant to the TS inhibitors RTX and U89 respectively, at concentrations where
100% of non-transduced cells were inhibited.

C. The effects of chemo-resistant marrow on tumor response to TS
Inhibitors.
In previous studies, chemo-resistant marrow expressing the OPTecTS
was transplanted into ApcMin/+ mice. Retroviral vectors based on the murine stem
cell virus (MSCV) promoter were constructed to express OPTecTS, while the
MSCV empty vector was used as controls. Lethally irradiated ApcMin/+mice were
reconstituted with chemo-resistant (OPTecTS) or control BMDCs, and and then
subjected to systemic treatment of a combination therapy of 5-FU and RTX or
PBS as control treatment. After the treated mice were sacrificed, intestinal
tissues were isolated and the tumor burden was determined. The results showed
that in mice transplanted with mock transduced marrow, systemic treatment with
5-FU caused a statistically significant decrease in tumor burden by approximately
75% from 32±19 (PBS) to 8±5 (5-FU/RTX) (p=0.008). In contrast, in mice
transplanted with drug resistant marrow expressing OPTecTS, tumors were not
as responsive to the therapy exhibiting a statistically insignificant reduction in
tumor burden from 35±22 (PBS) to 19±23 (5-FU/RTX) (p=0.183) (Pena et al,
unpublished data). These results showed that genetically modified chemoresistant bone marrow does influence tumor response to chemotherapy. These
preliminary data provides the basis for our working hypothesis that (1) tumor
response to chemotherapy is influenced by the sensitivity of tumor associated
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BMDCs and (2) it is possible that BMDCs can be genetically modified to chemosensitize both BMDCs and tumors to chemotherapy.

1.11 REVIEW OF LITERATURE (INHIBITION OF BMDCs)
A. Effect of systemic 5-FU therapy on tumor burden in ApcMin/+
mice
Tucker et. al. subjected ApcMin/+ mice to systemic treatment consisting of
three cycles of 40 mg/kg 5-FU administered intraperitoneal (i.p.) daily for five
consecutive days (Tucker, Davis et al. 2002). Mice were either immediately
sacrificed after the 5-FU regimen, or allowed to recover for 6-weeks post
therapy. At the end of the treatment regimens, intestinal tissue was removed
and tumor burden was assessed. The results showed that 5-FU reduced tumor
numbers by approximately 50% (p<0.001) compared to age matched control
groups treated with PBS.

In addition, weekly blood samples were collected to

assess the effect of 5-FU on leukocytes. The results showed a reduction in
leukocyte counts after exposure to 5-FU, and a return to normal or higher levels
upon cessation of 5-FU therapy. When mice were allowed to recover for six
weeks post therapy, there was no significant difference in tumor numbers
between mice treated with PBS or 5-FU. This suggested that 5-FU therapy was
only cytostatic to the tumor cells and after removal of therapy; the tumors
relapsed to the same level as that in untreated mice. This study showed that 5FU can inhibit tumor growth, but it also showed that it can affect the leukocyte
population in tumors and systemically in mice. The increase of leukocytes post
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therapy, particularly in the tumor stroma may contribute to the growth of tumors
post therapy. Thus, it is important to identify and further investigate the full
impact of 5-FU not just on leukocytes but also on other BMDCs in the
microenvironment such as mast cells, to determine their effect on tumor
response to therapy and recurrence post therapy.

B. Examining the effects of 5-FU on mast cells and precursors
A previous study from our lab examines the effects of 5-FU on subsets of
BMDCs, including mast cells, T regulatory (Treg) cells, and MDSCs in the tumor
stroma in the ApcMin/+ mouse (Acharya, G., et.al, unpublished data). Briefly, 14-15
week old mice were injected i.p. with a single dose of 50 mg/kg 5-FU. The mice
sacrificed at 3,5,7,9 and 12 days post therapy.

Tumors, spleen, and bone

marrow were collected, digested to create a single cell suspension and the
infiltrating BMDCs were quantified by flow cytometry. The results showed that
MDSCs were selectively sensitive to 5-FU while mast cells were resistant and
migrated to the tumor stroma in response to 5-FU while the Tregs were only
mildly sensitive to 5-FU. Analysis of apoptotic and proliferative indices of mast
cells and MDSCs showed that in mast cells, these indices were unaffected by
treatment with 5-FU. At 5 days post therapy, the number of mast cells infiltrating
the tumor stroma increased; this was accompanied by a corresponding decrease
in mast cell population in the spleen, suggesting that mast cells might migrate
from the spleen to the tumor stroma in response to 5-FU and molecular signals
from the residual tumor. In contrast, MDSCs had a high proliferative index that
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most likely rendered them vulnerable to 5-FU. The number of MDSCs decreases
by three-fold within 5 days of 5-FU administration in tumor stroma, spleen, and
bone marrow. However, they returned to pre-treatment levels within 10 days.
In another study, the effect of 5-FU on mast cell precursors was
determined in 8-week old C57BL/6 mice (Ophir, Berenshtein et al. 1993). Mice
were injected intravenously once with 0–150 mg/kg 5-FU. BMDCs were collected
at 2 and 4 days after injection and cultured in enriched media for 14 days to
stimulate the proliferation of mast cell precursors. Toluidine and alcian blue
staining identified mast cells. In response to 50 mg/kg the sub lethal dose of 150
mg/kg 5-FU, BMDCs retrieved on day 2 after 5-FU injection yielded 12.2±0.9%
and 2.6±0.3% mast cell precursors, while day 4 yielded greater than 80% and
60% mast cell precursors, respectively. Normal levels of mast cells were
observed by day 8 for the sub lethal dose. Data from the sub lethal dose
indicated that mast precursors were continuously activated or cycling after 5-FU
injection. Thus, there was gradual replacement, instead of recovery of mast cells
in the bone marrow compartment. These preliminary data collectively provides
evidence which support our working hypothesis that (1) tumor response to
chemotherapy may be influenced by the sensitivity of tumor associated mast
cells, and may interfere with tumor development, (2) effect of 5-FU on mast cells
may play a synergistic role to enhance its anti-tumor efficacy, or (3) inhibition of
mast cells may prolong tumor recurrence.
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1.12

RESEARCH GOAL
The preliminary data showed that tumor response to TS inhibitors was

influenced by the sensitivity of tumor associated BMDCs to the therapy. Genetic
modification of BMDCs to make them resistant to TS inhibitors also made tumors
resistant to the therapy. The goal of this project is to develop a therapeutic
strategy to target both cancer cells and non-cancer tumor stromal cells to
enhance the efficacy of TS inhibitors. I will examine the ability of reducing
intracellular TS levels by utilizing small RNA interference technologies against TS
to enhance sensitivity to TS inhibitors. Genetically modified BMDCs that are
sensitized to TS inhibitors are predicted to enhance the cytotoxic effects of 5-FU
within the tumor upon infiltrating the TME while protecting normal non-cancerous
cells from drug-induced toxicity.
In addition, I will test the hypothesis that pharmacological inhibition of
mast cell activity will also inhibit their pro-tumorigenic role within the TME will act
synergistically with 5-FU as well as prolong tumor relapse post therapy. My
overall goal is to target the TME to enhance the cytotoxicity of 5-FU to cancer
cells and to reduce tumor recurrence post therapy.

1.13

RESEARCH INNOVATION
The realization that tumor stromal cells have profound influence on tumor

behavior and tumor response to anti-neoplastic therapies is leading to a
paradigm shift in cancer therapy. These findings suggest that effective therapies
should also target these cells in addition to tumor cells.
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I will explore the

possibility that altering the sensitivity of the cells in the microenvironment will also
alter tumor response to therapy. I will use the Osteopontin (OPN) promoter that
is primarily upregulated and highly activated within tumor stromal cells to drive
the expression of a TS shRNA sequence to sensitize the infiltrating BMDCs and
the tumor prior to chemotherapy. The use of a promoter that is only activated in
the tumor stroma, will not only enhance tumor sensitivity to the therapy but will
also specifically direct tumor sensitivity to tumor cells while reducing toxicity to
normal cells. This strategy to enhance the efficacy and the specificity of
anticancer therapies can be applied not just too intestinal tumors but to other
classes of therapeutic agents in different types of tumors.
In addition, to modifying BMDCs I will use a drug known to specifically inhibit
mast cell degranulation during and post post 5-FU therapy to determine if mast
cells inhibition can synergize with 5-FU anticancer efficacy or prolong tumor
recurrence of tumor after chemotherapy. The novelty of inhibiting mast cells is
the utilization of the drug Cromolyn that has been used in treating asthma and is
readily available on the market. Even though this drug has displayed success in
reduction of various tumors, the combination of Cromolyn and 5-FU needs further
investigation.
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CHAPTER 2

DEVELOPING STRATEGIES TO INCREASE CHEMO-SENSITIVITY OF
CELLS TO THYMIDYLATE SYNTHASE INHIBITORS 1

_______________________________
1

Developing Strategies to Increase Chemo-sensitivity of Cells to Thymidylate
Synthase Inhibitors, Nikeya L. Tisdale, Karen W. Barbour, Maria
Marjorette O. Peña. To be submitted.
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2.1

ABSTRACT:
Thymidylate synthase (TS) is an essential enzyme necessary for DNA

replication and repair; it is responsible for the synthesis of thymidine. Typically,
cancer cells exponentially proliferate at higher rates, resulting in elevated TS
activity. Thus, using TS inhibitors has been promising in treating cancer.
Although, like any drug TS inhibitors do exhibit problematic pitfalls that include
harming normal non-cancerous cells, the occurrence of cancer resistance and
relapse to therapy. Attempting to circumvent these limitations, we used RNAi
vectors to suppress cellular levels of TS. Reduction of TS expression did
enhance sensitive to therapy, however the toxicity of the RNAi vector made it
impossible to examine the effects in vivo.

2.2

INTRODUCTION:
Thymidylate synthase (TS) is an enzyme that catalyzes the reductive

methylation of dUMP to produce dTMP and dihydrofolate (Danenberg 1977;
Carreras and Santi 1995). Subsequent, phosphorylation converts dTMP to dTTP,
an essential precursor for DNA synthesis. This catalytic activity provides the sole
intracellular de novo source of dTMP, thus TS is essential for actively dividing
cells.

Due to this, TS is an optimal target for anti-cancer therapies(Wilson,

Danenberg et al. 2014).Examples of TS inhibitors are 5-fluorodeoxyuridnine
(FdUMP), Raltitrexed, and 5-Fluoruouracil (5-FU).
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The most commonly TS inhibit is 5-FU which has been used in the clinical
management of many cancers. Inhibition occurs after 5-FU is transported into
cells and converted into several metabolites. One metabolite is FdUMP, a
powerful TS inhibitor. It disrupts DNA synthesis by forming a covalent ternary
complex with TS and the substrate 5,10-methylenetetrahydrofolate. Inhibition
results in the accumulation of dUMP, which is subsequently phosphorylated into
dUTP. The incorporation of dUTP into DNA, triggers DNA fragmentation and
ultimately cell death. Although, 5-FU is clinically used to treat cancer there are
some drawbacks to this therapy, such as acquired resistance and the lack of
specificity. Acquired resistance requires increase doses of 5-FU needed to kill
cancer cells; however, the dose administered is limited by its lack of specificity
resulting in toxicity to normal cells.
In addition, to its catalytic function, TS negatively auto-regulates its
intracellular protein level, by binding to its mRNA to block translation. To mitigate
the effects of 5-FU, TS protein bound to its mRNA are release to permit
translation leading to induction of TS protein, exhaustion of 5-FU, lowering cell
response and development of resistance to 5-FU. (Chu and Allegra 1996).
Another, disadvantage of 5-FU therapy is its lack of specificity, targeting both
actively dividing cancer and healthy non-cancerous cells. This leads to side
effects such as alopecia, myelosuppression, and mucositis, due to sensitivity of
non-cancerous cells in the hair follicles, the bone marrow compartment, and the
intestinal lining which are always cycling and are vulnerable to 5-FU. Thus, there
have been many attempts to enhance its efficacy while lowering toxic side by
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developing new therapies or technologies to be used in conjunction with 5-FU
(Natoli, Lupertz et al. 2013).
RNA interference (RNAi) is a novel technology that specifically lowers
cellular expression of a target gene of interest. It involves using short interfering
double stranded RNA (siRNA) or vectors driving the expression of short hairpin
sequences (shRNA) that are complementary to a target mRNA sequence.
Dependig on whether the siRNA is a perfect or imperfect match, binding to the
mRNA can cause its degradation or inhibit its translation, both resulting in
lowering the expression of the encoded protein (Hammond, Caudy et al. 2001;
Ku and McManus 2008). This technology has been beneficial in regulating gene
expression in cancers. A study targeting cyclin D1 with a silencing sequence
resulted in sensitivity to 5-FU (Seo, Jeong et al. 2013). More specifically a
number of studies have utilized RNAi against human thymidylate synthase in
cells to show that depletion of TS mRNA and protein levels can circumvent the
mechanism of resistance that occurs after exposure to TS inhibitors (Schmitz,
Chen et al. 2004; Yang, Cloud et al. 2006).
Although the use of RNAi against TS results to sensitize cells to TS
inhibitors is a promising strategy, these studies have only been performed in
cancer cell lines; the efficacy of this strategy and tumor response to this therapy
needs to be examined in mouse models in vivo. Targeting the TS siRNAs to cells
in the tumor strom to sensitize tumors to the therapy has not been explored and
provides a unique strategy to enhance antitumor efficacy.

32

The goals in this chapter are 1) to identify siRNA sequences that can
down regulated mouse TS expression in CHL (musTS) cell lines, 2) to determine
if the siRNAs can sensitize cells to TS inhibitors. We sought to chemo-sensitized
BMDCs to TS inhibitors by also using RNAi technologies against Mus musculus
thymidylate synthase (Mus TS), to establish a chemo-sensitive TME within the
ApcMin/+mouse model. Our results confirm that constitutive reduction of TS protein
levels enhances 5-FU efficacy. Yet, our attempts to observed chemo-sensitive
BMDCs response to therapy in ApcMin/+mice produced unfavorable results,
demonstrates some negatives of using RNAi for therapeutic applications.

2.3

MATERIAL AND METHODS:

Mus musculus TS expressing vector
A 1 kilo-base cDNA corresponding to LUC3-7 Mus musculus TS mRNA
was cloned into pBR322, a generous gift from Dr. Lee Johnson at Ohio State
University (Perryman, Rossana et al. 1986). This plasmid was used as a
template to PCR amplify mouse TS. The forward primer 5’ AAA AAA AGC TTT
TTG TCG CTG ACT ACA CTG 3’ inserts a HindIII site at position -37 and the
reverse primer 5’ TTT GTT AAC TTT TTT TTT TTA AAC AGC CAT TTC CAT 3’
inserts a HpaI site directly after a nine nucleotide poly A tail. The PCR amplified
fragment was cloned into pSV2CAT with the HindIII/ HapI sites, removing CAT
and replacing it with the 961 base pair amplified MusTS fragment. The resulting
plasmid, PSV2CAT-MusTS was stably transfected into the TS deficient CHL cell
line to generate the CHL (MusTS) cell lines expressing mouse TS.
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Generating CHL (Mus TS) cell line
Cell line RJK88.13, a TS deficient derivative of V79 Chinese hamster lung
(CHL) cells, was a generous gift from Dr. Robert Nussbaum from the University
of Pennsylvania(Nussbaum, Walmsley et al. 1985). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Corning Cellgro, Manassas, VA)
containing 4 g/L glucose, L-glutamine, sodium pyruvate, penicillin (100 U/mL),
streptomycin (100 mg/ml), 10% heat inactivated fetal bovine serum (FBS)
(Atlanta Biologicals Inc., Flowery Branch, GA) and supplemented with 10 uM
thymidine at 37°C with 5% CO2 in a humified incubator.
To generate CHL (MusTS) cell line the vector pSV2 (No CAT) expressing
mouse TS, PSV2CAT-MusTS was stably transfected into CHL cell line with
Liptofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Stable transfectants
were selected in media lacking thymidine in the presence of 5 mM dipyridamole,
a nucleoside transport inhibitor. Selected colonies were grown in mass culture.

Characterization of siRNAs against mouse TS in cells
siRNAs against mouse TS were designed using software by Dharmacon
RNA Technologies (Layette, CO) . The siRNAs were reconstituted in siRNA
buffer (Dharmacon RNA Technologies) (100μM stock solutions). The sequences
of two siRNAs against the Mus musculus TS mRNA sequence are: TS001 (GGA
GCA GAG TAC AAA GAT A) and TS003 (GGG TAT AAT CCA CAT CCA A).
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Twenty-four hours prior to siRNA transfection 1 ᵡ 106 cells were plated in
duplicate in 2 ml of DMEM with 10% FBS in a 6 well plate.

Cells were

transfected with either of the siRNA sequences using Dharmafect 1 transfection
reagent following manufacturer’s instructions (Dharmacon RNA Technologies).
Cells were collected post-siRNA exposure for immunoblot analysis.

Sensitivity to siRNA transfected cells to 5-FU
5 -Fluorouracil was purchased from Sigma-Aldrich (St. Louis, MO). Stock
solutions were made by dissolving in phosphate buffered saline (PBS) and filter
sterilized using a 0.22 uM syringe filter.

Two treatments with siRNA were

necessary to obtain sufficient down regulation of mTS during 5-FU treatment.
The first exposure induced the reduction of mTS protein level, while the second
exposure maintained the reduced protein levels for the duration of the treatment.
To evaluate the cytotoxic effects of 5-FU in combination with siRNA treatment,
0.5 x 105 CHL(MusTS) cells were plated in 1 mL DMEM with 10% FBS in
triplicate in 6 wells pates. Twenty-four hours later cells were transfected with 2
nM TS001 or scramble siRNA as control and allowed to incubate for forty-eight
hours. After down regulation of TS, cells were treated with increasing
concentration of 5-FU (0-1000 nM) and incubated for five days. Twenty-four
hours after the addition of 5-FU, cells were subject to 4 nM or 10 nM siRNA or
scramble siRNA. The second exposure ensured that TS was downregulated
during the remainder of 5-FU treatment. An additional control were cells treated
with 5-FU with no siRNA added.
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After 5 days, the cells were washed with Hanks buffered salt solution
(HBSS), trypsinized, and counted in the presence of trypan blue to distinguish
dead cells, using a hemocytometer.. The number of cells surviving at the end of
the treatment were expressed as a percentage of the number of cells surviving in
the absence of 5-FU.

Construction of plasmid for constitutive down regulation of MusTS
A double strand MusTS silencing oligo sequence was inserted into
linearized pSuper RNAi vector to express short interfering RNA against MusTS
(Oligo Engine, Seattle, WA). The silencing oligos contained the TS001 siRNA
sequence (target sense sequence), but with the addition of a hairpin loop
sequence TTC AAG AGA, the anti-sense sequence TAT CTT TGT ACT CTG
CTC C, and the restriction sites Bglll or HindIII on the forward or reverse oligo
respectively, resulting in two 60-nucleotide oligos (Integrated DNA Technologies,
Coralville, IA). The oligo strands were annealed together by mixing equal molar
concentrations, heating at 90ºC for 4 minutes, followed by annealing at 70ºC for
10 minutes, then gradually cooling to room temperature within 30-45 minutes.
The annealed oligos were then cloned into the BglII and HindIII restriction sites in
pSuper RNAi vector where their expression was under the control of the
constitutive RNA Polymerase III H1 promoter.
The resulting vector plasmid, pSuper-MusTS001 (8-10 ug DNA) was
transfected into CHL (MusTS) cells using Liptofectamine 2000 reagent. After 24-
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48 hours, cells were selected in 2 ug/mL puromycin (Invitrogen, Carlsbad, CA) to
generate a stable cell line.

Immunoblotting Assay and Quantification
Total protein extracts were obtained using M-PER protein lysis buffer
(Thermo Fisher, Waltham, MA) following manufacturer’s instructions. Gel
electrophoresis and membrane transfer were performed following standard
procedures.

Membranes were incubated in rabbit polyclonal anti-mouse TS

antibody (sc134130, Santa Cruz Biotechnology; 1:2000 dilutions in PBS-T/ 1%
milk) overnight at 4ºC, washed with PBS-T, and incubated with horseradish
peroxidase-conjugated anti-rabbit IgG antibody (BioRad; 1:1000 in PBS-T) for 1
hour at 20°C. The same membrane was with mouse monoclonal anti-mouse
actin antibody (β-actin-HRP ab49900, Abcam,) (1:1000 in TBS-T/1% skim milk,
1 h, 20°C). Bands were visualized using enhanced chemiluminescence plus
(ECL Plus; GE Healthcare) and a Konica SRX-101A film processor. Band
intensity was quantified using ImageJ software.
Mice
Animal experiments were conducted in accordance with the guidelines
and approval of the USC Institutional Animal Care and Use Committee. Mice
were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred and
maintained at the Mouse Experimentation Core Facility of the Center for Colon
Cancer Research at the University of South Carolina (USC), Columbia, SC.
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C57BL/6-UB1-eGFP mice transgenically express the enhanced green
fluorescent protein (eGFP), under the control of the human ubiquitin promoter.
These mice were used as donors for bone marrow transplantation (BMT), to
reconstitute lethally irradiated aged matched C57BL/6J-ApcMin/J mice (ApcMin/+).
Bone Marrow Isolation
C57BL/6-UB1-eGFP donor mice were anesthetized by inhalation of 2%
isoflurane in oxygen prior to sacrifice by cervical dislocation. Bone marrow (BM)
cells were flushed from the femur and tibia using a 21-gauge needle into PBS
containing 2% FBS. To quantify, red blood cells were lysed in ammonium
chloride solution and mononucleated cells were counted using a hemocytometer.

Transduction of CHL (Mus TS) cell line and Bone Marrow Derived Cells
CHL(Mus TS) cells were incubated in viral supernatant from GP+E86
producer cells stably transfected with pSuper retroviral vectors expressing
MusTS siRNA and scrambles siRNA containing 8ug/ml polybrene for 48 hours.
Stable transductants were selected in 2ug/ml puromycin.
For bone marrow transduction, donor mice were injected i.p,with 150
mg/kg 5-FU 48 hours prior to bone marrow isolation. Harvested marrow were
cultured in DMEM 20% FBS, recombinant murine interleukin 3 ( IL-3, 20 ng/ml),
recombinant murine interleukin 6 (IL-6, 20 ng/ml), and recombinant murine stem
cell factor (SCF, 50 ng/ml) in suspension culture dishes (Corning Incorporation,
Corning, NY) for 2 days. After 2 days, bone marrow cells were harvested and co-
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cultured with GP+E86 producer cells in the presence of 8ug/ml polybrene for an
additional 2 days.

Methylcellulose Assay
To

evaluate

chemo-sensitivity

of

transduced

mononuclear

cells.

Approximately 15000 cells plated in 1ml of methylcellulose in the present of RTX
(0-25nM) and 5µM dipyridamole. The number of progenitors was determined by
counting colonies after 7 to 14 days.

2.4

RESULTS:

2.4.1 Identifying an effective siRNA target sequences against MusTS
CHL(MusTS) were with two siRNAs TS001 or TS003, which were
complementary to nucleotides 487-505 or 958-976, respectively. Cells with the
siRNAs for 24-120 hours, their abilities to suppress TS expression were
assessed. Western blot analysis showed a decrease in protein levels over time
using both siRNAs (Figure 2.1a). Quantification of protein levels conveyed that
TS001 and TS003 suppressed TS expression by 63% and 82%, respectively,
within 24 hours, 14%, and 31%, respectively, by 48 hours (Figure 2.1b). Thus,
TS001 was more effective at inhibiting protein expression and was used in
further studies.
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2.4.2 Enhancing sensitivity to 5-FU by using TS001 silencing sequence
To determine if downregulating TS expression with TS001 siRNA will
sensitize cells to 5-FU, we treated cells with a second dose of TS001 siRNA

Figure 2.1: Down Regulation of MusTS with siRNA: a. Western blot analysis
showing suppression of Mus TS protein in CHL (Mus TS) cells during a time course
of 24-120 hours when exposed to 50nM of either TS001 or TS003 silencing
sequences. Actin was used as the loading control. b. Quantification of Mus TS
protein represented in percentages after exposure to Mus TS silencing sequences
at various times.

ensure that TS expression was repressed for the duration of the experiment.
Failure to maintain a sufficient level of siRNA made cells more resistant to 5-FU
(data not shown). Cells were initially treated with 2 nM of the TS001 prior to 5-FU
treatment. Twenty-four hours post 5-FU exposure, additional TS001 siRNA
added to a final concentration of 4 or 10 nM were sufficient to maintain
suppression of MusTS protein levels over the 5-day treatment (Figure 2.2a). The
results from the growth inhibition curves also showed that cells treated with
TS001 siRNA had lower IC50values. Cells exposed to either 4 nM or 10 nM final
concentration of TS001 in combination with 5-FU had IC50 values of 1.00 nM or
0.12 nM that were approximately 2.5- and 20- fold more sensitive, respectively,
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as compared to the control cells with an IC50 of 2.37 nM. Western blot analysis
showed down regulation of MusTS protein levels only in cells treated with TS001
siRNA (Figure 2.2b). Quantitation of the bands indicate that MusTS levels were

CHL(MusTS)
(2-10nM) TS001 siRNA
(2-4nM)TS001 siRNA
Scramb. SiRNA

Downregulating TS enhances the effects of TS inhibitor 5-FU
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Figure 2.2: Growth Inhibition Assay with siRNA: a. Growth inhibition curve
displaying enhancement of sensitivity towards 5-FU in CHL (MUS TS) cells
treated with various concentration of siRNA Mus TS sequence. IC 50 values
were 0.12nM, 1.00nM, and 2.37nM for cells treated with 10nM, 4nM, 0nM of
TS001 siRNA respectively. b. Western blot analysis of Mus TS protein of cells
in the absent of 5-FU and either treated with or without Mus TS silencing
target sequence (TS001). Cells treated with a final concentration of 10nM
TS001 siRNA displayed the greatest reduction of Mus TS protein. Actin was
used as the loading control. c. Quantification Mus TS protein after 5 days of
transiently transfected with TS001 siRNA and exposure to 5-FU treatment.
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reduced to approximately 93% and 85% in cells treated with 4nM or 10nM
TS001, respectively, as compared to cells with no siRNA or those treated with
scrambled siRNA (Figure 2.2c). These results showed that downregulation of
intracellular TS levels can sensitize cells to 5-FU. To translate these results in
vivo, it is important to develop expression vectors that will maintain reduced
MusTS levels in targeted cells constitutively as a mechanism to sensitize cells to
TS inhibitors.

2.4.3 Effects of constitutive expression of TS silencing sequence TS001
To investigate the effects of continuous expression of TS001 we
constructed pSuper retroviral vectors, which contains the RNA polymerase III
promoter, H1 to drive shRNA expression. The use of a retroviral vector, will
allow expression of silencing MusTS shRNA constitutively to maintain sensitivity
to TS inhibitos in vitro and in vivo without having to add additional siRNA.
Transduction of CHL(MusTS) cells line or bone marrow derived cells with the
retroviral vectors showed that constitutive expressesion of TS001 shRNA
rendered cells more sensitive to 5-FU as compared to the cells transduced with
control empty vector or scrambles shRNA (Figure 2.3a). We observed IC50 values
of 33.07 nM, 2.69 nM, and 44.89 nM for cells expressing pSuper vector control,
TS001 shRNA, or the scrambled shRNA, respectively. Thus, cells expressing
TS001 shRNA were approximately 13-16-fold more sensitive to 5-FU as
compared to cells expressing scrambled shRNA or empty vector. Western blot
analysis showed that MusTS levels were downregulated only in cells expressing
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the TS001 shRNA retroviral vector (Figure 2.3a). MusTS levels in these cells
were 40% less as compared to the control cells (Figure 2.3b). This reduction of

pSuper
pSuper-TS001
pSuper-scramble

a.

Constitutive down regulation of TS enhances effect of TS inhibitor 5-FU
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Figure 2.3: Growth Inhibition Assay with pSuper Constitutive Vector: a.
Growth inhibition curves of CHL (Mus TS) cells that were transduced with
retroviruses to express the pSuper vectors or a silencing or a scramble
sequence against Mus TS. All cells were exposed to increasing
concentration of 5-FU to determine IC50 values. CHL (Mus TS) cells
expressing the silencing sequence display more sensitivity to 5-FU. IC50
values are 33.07nM, 2.69nM, 49.48nM for pSuper vector control, pSuperTS001, and pSuper-scramble respectively. b. Western blot analysis of CHL
(Mus TS) transduced with pSuper retroviral vector expressing either TS001
shRNA or the scramble sequences. Reduction of Mus TS protein is only
observed in cells transduced with the silencing sequence. c. Quantification of
the Mus TS protein shows the shRNA sequence reduces the expression of
Mus TS protein by approximately 40%.
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MusTS

protein confirmed that the shRNA retroviral vectors were functioning

appropriately and that we have constructed an efficient shRNA vector against
MusTS that is able to sensitized cells to 5-FU by suppressing protein levels. Next
we transduced bone marrow cells to determine if these vectors can sensitize
bone marrow cells to TS inhibitors. Transduced bone marrow progenitor cells
where plated in methylcellulose in the presence of increasing concentrations (0
nM-25 nM) of the TS inhibitor, raltitrexed. Approximately 50% growth reduction

a.

Colonies Genomic DNA

CTL

Vector

b.

1

2

3

pSuper
TS001

Figure 2.4: Examining Sensitivity of Transduce BMDCs expressing pSuper
vectors: a. Colonies counts of bone marrow derived cells transduced to express the
retroviral vector pSuper or pSuper-TS001 treated with increasing concentration of
raltitrexed. Bone marrow expressing the Mus TS shRNA shows increase sensitivity to
raltitrexed for exposure to 10nM concentration no colonies formed, however colonies
developed in both the control groups. b. PCR amplification of colonies that were in the
absent of raltitrexed to confirm expression of retroviral vector pSuper of pSuper-TS001.

was observed in BMDCs that were constitutively expressing the MusTS shRNA
in the presence of 5 nM RTX when only 88% or 75% growth reduction was
observed in non-transduced or vector controls, respectively. In addition, colony
growth at 10 nM RTX was observed in only the control groups but not in BM cells
transduced with TS001 shRNA (Figure 2.4a), supporting the idea that the
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addition of an shRNA against MusTS is effective in sensitizing BMDCs to TS
inhibitors. These results confirmed our ability to enhance the efficacy of TS
inhibitors with the utilization of RNA interference technology. The question then is
whether we can apply these strategies to sensitize the tumor microenvironment
in vivo.

Figure 2.5: Non-recovery of MusTS expression in BMDCs
expressing pSuper vectors: Colonies counts of bone marrow
derived cells transduced to express the retroviral vector pSuper or
pSuper-TS001 in the present or absent of thymidine. The addition of
thymidine does not recovery the colonies counts for bone marrow that
expresses either pSuper or pSuper-TS001 vectors.

To determine if the sensitization of bone marrow cells by TS001 shRNA in
vitro can be recapitulated in mouse models in vivo, BMDCs transduced with
pSUPER-TS001 shRNA were transplanted into lethally irradiated ApcMin/+ mice.
However, reconstituting mice with BMDCs expressing either pSuper vector
control or pSuper shRNA resulted in immediate death of the recipient mice. Since
mice subjected to transduced bone marrow did not survive to engraftment, we
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were unable to examine the effects of chemosensitive BMDCs in vivo. To
determine if the constitutive down regulation of TS was the cause of the
unsuccessful attempts to reconstitute irradiated mice, BMDCs transduced with
the retroviral vectors were plated onto methycellulose in the presence or absence
of thymidine and growth of progenitor cells were assessed and compared to nontransduced cells. The results showed that the number of colonies did not differ
significantly with the addition or lack of thymidine (Figure 2.5). Thus, the failure of
thymidine to rescue transduced BMDCs from toxicity suggested that the retroviral
vector pSuper was most likely problematic and toxic. To resolve this issue we
used a different RNAi vector expressing system.

2.5

DISCUSSION:
In this study, we investigated effect of diminished MusTS expression on

the sensitivity of CHL (MusTS) or transduced bone marrow cells to TS inhibitors
using siRNA technology. We identified an siRNA sequence that reduced
translation of MusTS mRNA by approximately 37%. Transfection of the siRNA or
transduction of its corresponding shRNA in both CHL(MusTS) or bone marrow
cells effectively sensitized cells to the TS inhibitor 5-FU.
Initially, to observed the response to therapy transiently transfecting cells
with the2nM TS001 siRNA, displayed a resistance phenotype when expose to 5FU (data not shown). Plausibly reasoning for resistance is due to the delayed
decrease in protein levels, due to using low concentration of the siRNA.
However, resolving this problem by exposing the cells to higher concentration of
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the siRNA could drastically affect proliferation and hamper cells response to
therapy. Therefore, we decided to expose the cells to the low concentration of
siRNA before therapy for the delay decrease in TS expression, providing
sensitivity, and then gradually increase the concentration of the siRNA for the
duration of the therapy to inhibit in additionally translation of the mRNA to reduce
TS expression. Thus, to evaluate siRNA technology capability of sensitizing cells
to TS inhibitors, it was necessary to establish slight reduction of protein level
before therapy followed by a prolonged disruption in the ability to translate the
mRNA, for the duration of the therapy. Indeed, we found that transfecting cells
with a low concentration of the siRNA prior to 5-FU exposure induce sensitivity.
However, to accomplish long-term reduction of protein expression, the addition of
more siRNA was needed twenty-four hours after 5-FU treatment, resulting in a
final concentration of either 4nM or 10nM of the siRNA, which ensuring prolong
down regulation of the protein, resulting in enhanced sensitivity towards 5-FU.
Our results show an equivalence of either a 2 or20- fold increase in chemosensitivity, of cells transiently transfected with either 4nM or 10nM TS001 siRNA
respectively in the present of 5-FU.From these results, we established that
siRNA technology is able to sensitized cells to chemotherapy. Nevertheless, is
problematic and is not conductive for in vivo studies. The problem of providing
efficient and permanent reduction of Mus TS gene expression was resolved only
by the addition of more siRNA, yet this is a solution for in vitro studies is not
conceivable in the attempt to sensitizing the TME in the ApcMin/+mouse model.
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Therefore, it is necessary to use an RNA interference system that is vector
base, and which we utilized the H1 promoter in the pSuper retroviral vector to
drive the expression of the Mus TS shRNA to provide a permanent reduction in
the Mus TS gene expression. The utilization of this retroviral vector allowed us
the ability transduced CHL (Mus TS) and mouse bone marrow derived cells to
express the shRNA against TS, such to develop and enhance sensitivity to TS
inhibitors. Promising result from CHL (Mus TS) cells expressing Mus
TSshRNAdisplayed13-fold increase in chemo-sensitivity towards 5-FU. We
observed approximately a 40% reduction of protein expression, which is strikingly
greater than the protein reduction observed from siRNA technology. Although,
promising this 40% reduction in protein expression that occurred in CHL (Mus
TS) cells, may translate into proliferation problems when expressed by BMDCs.
For the delivery of Mus TS shRNA sequence within the TME of ApcMin/+ mice is
contingent on the ability of bone marrow derived cells to proliferate, imperative
for infiltration into the TME.
To assess this issue, retroviral particles were used to transduce bone
marrow derived cells to examine the effects of stably incorporating the pSuper
vector into the genome of these. The genetic modulate bone marrow derived
cells expressing the Mus TS shRNA was used for both concurrent ex vivo and in
vivo chemo-sensitive studies, for both studies required time for either colony
formation or reconstitution engraftment of ApcMin/+mice that were subjected to
irradiation to completely deplete existent bone marrow. Our ex vivo results of
transducing mouse bone marrow derive cells to express the MusTS shRNA
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sequence showed promising effects, of chemo-sensitivity toward raltitirexed.
However, the occurrence of fatalities in ApcMin/+mice reconstituted with bone
marrow expressing Mus TS shRNA seems to hinder cells ability to proliferate,
due to cytotoxic effects. The data in which we attempt to recover cellular
thymidine level with the addition of exogenous thymidine in BMDCs implicates
that the pSuper vector is indeed toxic. The inability to recover colony formation in
either vector control or shRNA expressing BMDCs proves that the pSuper vector
system is problematic.
Additionally, this in vivo result suggests that down regulation of Mus TS
gene expression needs to regulate. TS is an essential enzyme for cell
proliferation and to continuously suppress it’s expression is sure to have
devastating outcomes, thus, in the future we intend to use an inducible promoter,
one that activates only in the tumor microenvironment. In hopes to alleviate, any
problem caused by the constitutive down regulation of Mus TS.
Overall our data suggest that the down regulation of MusTS expression
prior exposure to chemotherapy is beneficial in reducing the concentration of 5FU required to inhibit cellular proliferation. These results are the effect of the
mechanistic degradation or inhibition of translating of Mus TS mRNA that is
target by RNA interference technology. The process of subjecting cells first to
target Mus TS RNA interference disrupts cellular translation of the TS protein.
The reduction in cellular protein levels is advantageous for requirements of
inhibiting the catalytic activity of the protein have lessened. In addition the
additive effect of utilizing RNA interference in combination with TS inhibitors

49

eliminates the induce activation of protein production, for MusTS mRNA is
targeted for degradation prohibiting translation.
Clearly, many problems can occur with utilizing RNA interference
technologies. However, used appropriately it may be beneficial in a variety of
clinical disease processes.
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CHAPTER 3

CHARACTERIZATION OF THE ABILITY OF THE MURINE
OSTEOPONTIN PROMOTER TO DRIVE THE GENE EXPRESSION
SPECIFICALLY IN BONE MARROW DERIVED CELLS IN THE TUMOR
MICROENVIRONMENT2

______________________________
2Characterization

of the Ability of the Murine Osteopontin promoter to Drive
Gene Expression Specifically in Bone Marrow Derived Cells in the Tumor
Microenvironment, Nikeya L. Tisdale, Sapana N. Shah, Celestia Davis,
Maria Marjorette O. Peña. To be submitted.
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3.1

ABSTRACT:
Osteopontin (OPN) has been implicated as a cytokine that plays an

important role in cancer progression. It is secreted by a number of cells and jas
been shoen to activate the function of many immune cells. Studies investigating
the activity of the osteopontin promoter showed that it contains many enhancer
sites, which are influenced by inflammatory stimuli. Here, we show that the
regions encompassing (-777/-740 to +79) of the OPN promoter is responsive to
inflammatory stimuli and can specifically be activated only in the tumor
microenvironment of APCMin/+ mice. In addition, we have validated that the OPN
promoter has the capacity to drive the expression of an RNAi sequence. The
results of these studies indicate that the OPN promoter may be useful in directing
the expression of chemo-sensitizing genes specifically in stromal cells in the
tumor microenvironment. These will be useful in testing our central hypothesis
that by sensitizing tumor stromal cells, it is possible to sensitize cancer cells to
the therapy.

3.2

INTRODUCTION:
Endogenous gene silencing is mediate by microRNA (miRNA). The

development and maturation of miRNA begins in the nucleus, where miRNAs
are transcribe as part of long primary transcripts (pri-miRNAs), which contain
multiple embedded hairpins. Drosha/Pasha, RNASE III enzymes cleaves these
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pri-miRNAs into individual stem loops within the nucleus. These individual stem
loops are precursor miRNAs (pre-miRNAs), which are approximately 70nt length
double strand sequences (Yeom, Lee et al. 2006). Pre-miRNAs are exported
out of the nucleus by the protein Exportin 5 into the cytoplasm, to further,
undergo processing by RNASE III enzymes, Dicer and RNA-induced silencing
complex RISC to obtain gene silencing (Ku and McManus 2008). Dicer removes
the stem loop structure to produce a ̴ 21-23nt long double stranded sequence,
which is then subsequently incorporated into the RNA-induced silencing
complex (RISC)(Hammond, Caudy et al. 2001). The RISC uses one strand of
the double strand RNA as a guide to target the mRNA of interest for degradation
or inhibition of translation, thus resulting in lowering expression of the encoded
protein (Ku and McManus 2008). This mechanism of gene silence provides the
template for exogenous mediated gene silencing accomplished by small
interfering (siRNAs) or short hairpin RNAs (shRNAs).
The widely utilized commercial synthetic siRNAs are ideal to examine the
functional roles of genes in upstream and downstream processes during
disease development. Upon entry into the cytoplasm of cells, the cytoplasmic
enzymes of miRNA machinery process siRNAs to achieve inactivation of genes.
Even though it has been advantageous, the utilization of siRNAs has limitations
that include the inability to enter slowly dividing cells and the inability to sustain
continuous suppression of gene expression. To circumvent these issues the
development of shRNA viral expression vectors are modeled after pre-miRNAs.
Typically, to provide constitutive repression of a gene, shRNA viral vectors
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employed RNA polymerase (pol) lll promoters, H1 or U6 to control the
expression of the shRNA sequence(Paddison, Caudy et al. 2002; Rossi 2008) .
However, these vectors can be problematic, causing RNAi toxicity and they lack
the capacity to be tissue specific (Boudreau, Martins et al. 2009) as previously
discussed in Chapter2.
Thus, modifications to shRNA expression vectors were developed to be
more similar to pri-miRNA, by embedding the shRNA sequence into an
endogenous miRNA backbone (shRNA-miRs), such as miR30 (Matveeva,
Nazipova et al. 2012; Fellmann, Hoffmann et al. 2013). The advantage of this
feature is that it enables the expression of the shRNA to be controlled by a RNA
Polymerase II promoter. Additionally, this model system exploits the entire
miRNA processing machinery resembling the natural maturation of gene
silencing within a cell. This particular system eliminates the need to use a pol III
promoter to drive the expression of a silencing sequence. Thus, we decided to
use this model system to circumvent the problems that occurred when utilizing
the constitutive retroviral vector pSuper, which uses the H1 promoter to drive the
expression of the silencing sequence. We show that using the murine
cytomegalovirus promoter (mCMV) a polymerase II promoter driving the
expression of TS silencing sequence is an ideal expression system that will
allow us to examine the systemic effects of reducing TS expression in mice.
The processes of gene expression is regulated by several influential
factors such as frequency of transcription of a gene, post-transcription
modification of messenger RNA, translation, and maturation or degradation of
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protein. These regulatory processes enforce the balance of gene expression,
which controls cellular function or development. Regulation of gene expression
can be tissue specific, which is typical during developmental progression and the
processes of wound healing or cancer. Reproducing and using the regulatory
features of tissue specific gene expression can be beneficial for targeting
therapies, hence alluding to the capacity to target only the tumor and its
microenvironment.
In devising the approach for specific targeting, it was essential to identify a
gene that is only activate and expressed in the TME; and then use this gene’s
promoter to drive the expression of an RNAi sequence against thymidylate
synthase. We identified Osteopontin (OPN) as a potential candidate, since
studies have shown that it plays a vital role in the progression of cancer, and is
highly expressed in several tumors.
The emerging evidence pertaining to OPN involvements in cancer
development has led to its consideration as a biomarker (Cao, Li et al. 2012).
OPN is a secretory extra cellular matrix (ECM) protein that is secrete by a variety
of cells such as endothelial, epithelial, and activated immune cells. Results have
implicated the involvement of OPN in the interactions that occur between cancer
cells and its tumor stroma (Gotoh, Sakamoto et al. 2002). OPN is highly
expressed in a variety of human cancers. In particular, in human gastric cancer
OPN has been shown to be highly expressed in gastric cancer lesions, mildly
expressed in the tumor stroma, and is negatively expressed in the normal
regions of tissue sections(Ue, Yokozaki et al. 1998; Junnila, Kokkola et al. 2010).
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In addition, a study comparing the alteration of gene expression in normal versus
tumor intestinal tissues revealed elevated levels of OPN in the polyps of APCMin/+
mice (Chen, Hao et al. 2004).
Moreover, several studies have indicated that pro-inflammatory stimuli
induce the transcription of OPN gene (Guo, Cai et al. 2001; Denhardt, Mistretta
et al. 2003; Zhu, Denhardt et al. 2005). Guoet.al. demonstrated that the OPN
promoter activity increased in the presence of lipopolysaccharide (LPS) and nitric
oxide (NO). Furthermore, examination of OPN promoter identified several
regions as pro-inflammatory response elements such as ras- activated
enhancers that promoted the transcription of the gene in metastatic transformed
cells or in cells exposed to hypoxic conditions(Guo, Zhang et al. 1995; Zhu,
Denhardt et al. 2005).

In addition, identification of positive and negative

regulatory cis- acting elements in various regions of the OPN promoter influences
tissue specific expression (Higashibata, Sakuma et al. 2004). The premises of
these studies indicate that the OPN promoter is an ideal candidate to use to
target specifically the TME.
Once, again all roads leads back to the TME stressing the importance of
infiltration of BMDCs and their function in tumor progression and resistance to
various chemotherapies. Important players in tumor progression that also, exhibit
immune suppressive activities include mast cells; myeloid-derived suppressor
cells (MDSCs) and regulator T cell (Tregs). Mast cells are effectors cells that
release an array of pro-inflammatory mediators, which have shown to influence
the migration and function of many hematopoietic derived cells in cancer
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progression (Ribatti 2015). Crosstalk between mast cells and MDSCs was
observed in a CT26 cancer model and was shown to enhance the suppressive
activities of MDSCs (Danelli, Frossi et al. 2015). MDSCs are a heterogeneous
population of immature myeloid cells that are activated by the pro-inflammatory
stimuli produced within the tumor or by mast cells. Activation of these cells
results in suppression of T cell activation, which is necessary for antitumor
immunity, permitting the immune system to be acceptance to tumor progression
(Marvel and Gabrilovich 2015; Parker, Beury et al. 2015). MDSCs production of
interleukin 17 (IL-17) have been shown to reinforce it suppressor functions by
indirectly attracting regulatory T cells into the tumor (Yang, Zhang et al. 2010).In
the presence of 5-FU, depletion of MDSCs have shown to result in two
outcomes. First, the beneficial outcome results in the enhancement of T cell
dependent antitumor activity (Vincent, Mignot et al. 2010). The other outcome
supports tumor growth due to the secretion IL-1B by MDSCs, which recruits
Tregs to produce IL-17 to assist with angiogenesis (Bruchard, Mignot et al.
2013). The effect of 5-FU on tumor infiltrate mast cells response has not been
elucidate, however reduction in mast cell progenitors followed by a rapid
recovery was observed in the bone marrow and spleen of mice (Hokari, Tsuboi et
al. 2011).

These studies highlight the importance for why chemotherapy

sensitivity needs to be established in these particular BMDCs populations.
Hence, reprogramming of these cells to be genetically more sensitive to therapy
may be beneficial to how these BMDCs respond to therapy.
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Thus, we sought to determine if utilizing the inducible characteristic of the
OPN promoter could drive the expression of an RNAi sequence against Mus TS
specifically within the tumor microenvironment to establish chemo –sensitivity of
these cells to TS inhibitor. To accomplish this we demonstrated the OPN
promoter (-740/ -777 to +79) regions are responsive to pro-inflammatory stimuli
and are capable of driving the expression of mCherry a fluorescent protein only
within the tumor microenvironment of APCMin/+mice. In addition, we validate that
the -740 to +79 OPN promoter region is capable of driving the expressing of
RNAi sequence against MusTS to enhance cellular sensitivity to 5-FU. The
premises of our studies show that the OPN promoter can indeed provide specific
chemo-sensitivity in the TME.

3.3

MATERIAL AND METHODS:

Lentiviral vector
We obtain the pZip lentiviral vector from Transomic Technologies. Dr.
Greg Hannon and colleagues from Cold spring Harbor Laboratory developed this
system, which is comprised, of an ultramiR scaffold shRNA, fluorescent marker
Zsgreen, and the selectable marker puromycin constitutively driven by the
mCMV promoter to establish efficient repression of a target gene. The MusTS
shRNA

sequence

expressed

by

this

vector

is

the

following:

TGCTGTTGACAGTGAGCGACAAGACCTTTCCCAAAGCTCATAGTGAAGCCA
CAGATGTATGAGCTTTGGGAAAGGTCTTGGTGCCTACTGCCTCGGA. The
lentiviral vectors were stably transfected into CHL (MusTS) cells following
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manufacturer’s instructions. Selection of stable transfectants was done by
incubating transfected cells with puromycin antibiotics and visual verification of
Zsgreen expression in cells fluorescence microscopy and flow cytometry.

Vector Construction
Vector pXP1-OPN (-777 to +79) was a generous gift from Dr. David T.
Denhardt from Rutgers University. Regions -777 to +79 and -749 t0 +79 were
PCR amplified using the forward primers: GGT ACC ATG CAT CTG CTC CAA
CAG AGC AAC AAG GTT C or GGT ACC ATG CAT TCT CTA AAG GTC AGT
GGA GGC AGG, respectively, and the reverse primer: AAG CTT GAT ATC ACC
GGT CTT GGC TGG TTT CCT CCG AGA ATG. Amplified regions were cloned
into the retroviral vector pMSCV that contained the mCherry fluorescent protein.
These retroviral vectors were transfected into viral producer cell line GP+E86.
The pZip lentiviral vectors were used to construct lentiviral vectors
containing the OPN promoter. The MSCV promoter was replace with the OPN
promoter by recombination cloning following manufacturer’s protocol for
(Clonetech Infusion Cloning kit). Manufactures protocol for transfection was use
to establish stable expression of the vectors in CHL (MusTS) cell line (Transomic
Technologies). Confirmation of stable expression was acquired by exposing
transfected cells to puromycin antibiotics and visual verification of Zsgreen
expression in cells.
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Transducing bone marrow derived cells
Dr. Boris Kantor of the Vector Core at the University of South Carolina
produced the viral particles for the lentiviral vectors in the pZip backbone. . These
viral particles were used to transduce bone marrow for reconstitution of lethally
irradiated mice.

Lethal irradiation and reconstitution of ApcMin/+or Balb/c mice
Four-week-old recipient ApcMin/+ mice were lethally irradiated utilizing the
JL Shepard Cesium-137 irradiator by administering 190 rads/min for a total of
950rads. 2–3 × 106 genetically modified mono-nucleated cells were transplanted
into the lethally irradiated mice by tail vein injection within eight-hours of
irradiation. Transplanted mice were administered sterile water containing 0.004%
Baytril antibiotic (Bayer Animal Health Division, Shawnee, KS) for two weeks
post-transplantation to prevent infection. These mice were used to determine if
the OPN promoter is only activated within the intestinal tumor regions of a mouse
model. Confirmation of successfully engraftment of genetically modified BMDCs
was obtained 6 to 8 weeks post transplantation by bleeding mice and isolating
genomic DNA from leukocytes. Genomic DNA was PCR amplified with primers to
confirm incorporations of the mCherry gene.
Reconstituted 15-week old ApcMin/+ mice were humanely sacrificed by
cervical dislocation. Their intestines were isolated, flushed with 1xPBS and cut
open longitudinally. The tissues were fixed in 4% paraformaldehyde overnight.
The fixed intestines were then swiss-rolled and embedded in paraffin cassettes
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and left to dry overnight. 3-5 micron sections were mounted on standard
microscopy slides and nuclei were stained with Dapi.
Four-week-old recipient Balb/c mice were lethally irradiated using the JL
Shepard Cesium-137 irradiator by administering 950 rad at 190 rads/min.
Transplantation and verification of engraftment of genetically modified marrow
was performed as described above.

Flow Cytometry
BMDCs were isolated from the femur, tibia, and blood from recipient mice.
The single suspensions were incubated in ammonium chloride lysis buffer (150
mM NH4Cl, 10 mM Na2CO3, 0.1 mM EDTA, pH 7.4) for 5 minutes on ice, in the
dark to lyse the red blood cells, followed by centrifugation at 2000 rpm for 5
minutes at room temperature and the supernatant discarded. Excess lysis buffer
was removed by washing the pellet twice with cold PBS containing 2% FBS and
then centrifuged at 2000 rpm for 5 minutes. The cells were counted using a
hemocytometer, and approximately 2 million cells were stained with antibodies
against the cell surface markers CD45 for leukocytes, CD8a and CD8a for T
cytotoxic cells, CD34 and CD117 for mast cells, CD4 and Foxp3 for T regulatory
cells, and GR1 and CD11b for MDSCs for 1 hour at 4°C. To determine apoptosis
index antibodies against Annexin V and Viability Dye eFluro 780 were used to
stained particular cell populations. Antibodies against Ki67 determined the
proliferation index for the different cell population. All antibodies for flow analysis
obtained from Ebioscience. Excess antibodies were removed by washing cells
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once with cold PBS containing 2% FBS and then centrifuged at 2000 rpm for 5
minutes. The cell pellet was then resuspended in 500µL of PBS containing 2%
FBS for flow cytometry analysis using a Beckman Coulter FC-500 flow
cytometer.

Immunofluorescence
The sections were deparaffinized, rehydrated, and then incubated in a
microwave oven

at 95oC with 0.01 M citrate buffer, pH 6.0 (Diagnostic

Biosystems, Pleasanton, CA) for 10 minutes for antigen retrieval. Sections were
blocked with 5% BSA for one hour. To identify apoptotic cells, the samples were
incubated for 2 hours at 37oC. with a mixture of primary antibodies against
cleaved PARP-1 (Rabbit polyclonal, 1:200 dilution, Santa Cruz Biotechnology,
Santa Cruz, CA USA) and a cell-type specific cell surface marker such as CD11b
for monocytes, Ly-6 for granulocytes, or c-kit for mast cells (all the antibodies
are rat monoclonal used at 1:200 dilution, all from Abcam, Cambridge, MA) in 1%
BSA in PBS. Samples were wash twice 1XPBS and stained with respective
secondary antibodies conjugated to Cy-3 (surface markers) or Cy-5 (Parp-1) for1
hour at 37oC. The sections were again washed with 1XPBS and then stained
with DAPI. Stained sections were treated with ProLong Gold anti-fade reagent
(Invitrogen, Frederick, MD) prior to applying the cover slips.
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Confocal Microscopy
The slides containing sections stained with the various combinations of
primary antibodies were imaged using Zeiss LSM Meta 510 confocal microscope.
For each antibody combination, approximately 100 field view images were
captured at 40 X magnification.

For each field view image, cells that stained

positive for the specific cell surface markers were counted and scored as
apoptotic if they also stained positive for cleaved PARP-1. Apoptotic indices were
calculated as the percentage of cells that stained for both the cell surface marker
and cleaved PARP against the total number of cells that stained positively for the
specific cell surface marker.

3.4

RESULTS:

3.4.1 Examining the capacity of mCMV promoter to drive the expression of
an RNAi sequence against TS in vitro and in vivo
To determine if the murine polymerase II promoter is able to drive the
expression of an RNAi sequence against MusTS, we stably transfected the
pZiplenti-viral vectors into the CHL(Mus TS) cell line to observe suppression of
TS protein levels. Cells that were stably transfected with the pZip-mCMV-TS
shRNA vector displayed a 67% expression of the protein and a 0.43 fold
reduction in TS mRNA levels in these cells (Figure 3.1) when compared to the
non-transfected cells. In addition, we observed a slight reduction of protein and
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mRNA expression in the vector control cells, which was of concern due to the
possibility that the vector might also prove to be toxic to transduced cells in an in
vivo model. Thus, we determined the effect of expressing the lentiviral vectors on
the growth rate of transduced cells as compared to control cells and nontransduced cells. Twenty thousand cells were plated and the growth rate was
monitored over 6 days. The results showed that there were no differences in the
growth rates between these cells (Figure 3.1) providing assurance that the lentilviral vector system did not impair cellular proliferation and, thus may not be
detrimental in an in vivo model system. To determine of the 33% reduction in
MusTS level was sufficient to sensitize cells to 5-FU, we performed a growth
inhibition assay. The results showed that there was no increase in the sensitivity
to 5-FU of cells that expressed the RNAi sequence against MusTS as compared
to control cells expressing the empty vector (Figure 3.1). Despite its inability to
enhance sensitivity, most importantly, it was necessary for us to determine if this
vector system can be used to modulate BMDCs for successfully engraftment into
tumor-bearing mice.
To examine the effects of transplanting BMDCs transduced with the
pZiplenti-viral vectors in vivo, BMDCs were isolated from donor Balb/c mice and
transduced with viral particles from either the pZip-mCMV control vector or pZipmCMV-TS shRNA vector using a multiplicity of infection of five. This resulted in
approximately 20% of the BMDCs population expressing either vector as
confirmed by fluorescence activated cell sorting (FACS) analysis to detect
Zsgreen protein expression. This fluorescent marker in the pZip vector backbone
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was used to confirm incorporation of vector into the cell’s genomic DNA and its
expression within transduced cells. We used the bone marrow that was 20%
Zsgreen (ie, transduced) to transplant and engraft into lethally irradiated Balb/c
mice. The controls for this study were Balb/c mice reconstituted with BMDCs that
expressed the vector control that contain the Zsgreen gene under the control of
the mCMV promoter or GFP expressing transgenic BMDCs.
Four weeks post transplantation, genomic DNA from mice reconstituted
with genetically modified bone marrow was extracted from the blood to confirm
incorporation of the Zsgreen gene and the Ultramir 3’ and 5’ regions with the
RNAi control or RNAi Mus TS sequence in the genome (Figure 3.2). This result is
significant for since have identified an RNAi system that is safe to use in mice.
Thus, by using the pZip-mCMV vector we confirmed that an polymerase ii
promoter can drive the expression of an RNAi sequence against MusTS, and this
RNAi vector system can be used to modulate BMDCs to successfully engraft in
mice without exhibiting cytotoxic effects. These results suggest that we
potentially have capability to direct tumor stromal specific sensitivity to
chemotherapy drugs in an in vivo model. The potential to establish specific
sensitivity is dependent on the ability of the promoter to drive the expression of
the RNAi sequence. We identified the OPN promoter as a possible candidate.
However, further examination of the promoter is necessary before the
implementation of this RNAi vector system into in vivo mouse model of cancer.
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a.

b.

c.

d.

e.
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Figure 3.1: Examining the ability of mCMV Promoter to control an RNAi sequence. a. Depiction of the lenti-viral
pZip-mCMV vector map. b. Western blot analysis of CHL (Mus TS) stably transfected with pZip lenti- viral vector
containing the mCMV promoter to drive the expressing both shRNA sequence and Zsgreen or the vector control which
only drive the expression of the Zsgreen protein. Reduction of Mus TS protein is only observed in cells transduced with
the silencing sequence. c. Quantification of the Mus TS mRNA shows the shRNA sequence reduces the expression of
Mus TS protein by approximately 33%. d. Growth curve graph indicating that the growth rate of cells expressing the
shRNA sequence is comparable to control cells or the cells expressing the vector control. e. Growth inhibition assay
show that pZip vectors exhibit sensitivity to 5-FU therapy.

3.4.2 Characterizing the specificity and induciblity of the OPN promoter
regions (-777/-740 to +79)
To determine responsiveness to inflammatory stimuli of the OPN promoter
(-777/-740 to + 79) driving the expression of the gene encoding the mCherry
fluorescent gene, cells transfecyed with these constructs were treated with
different inflammatory stimuli. We exmined the expression of the mCherry reprted

Vector

gene by microscopy and by immunoblot analysis of mCherry protein levels to

ZsGreen
Ultramir 5’/3’ +
RNAi control
or RNAi Mus TS

Figure 3.2: Confirming incorporation of pZip-mCMV lenti-viral vectors in
vivo. a. Depiction of extracting BMDCs from donor Balb/c mice for genetic
modulation of cells with lentil-viral particles to express either mCMV-Zsgreen
or mCMV-ZSgreen-TS shRNA sequence to transplant into lethally irradiate
Balb/c mice recipients. b. Confirmation of successful reconstitution of
transduce BMDCs into recipient mice by PCR amplifying genomic DNA to
detect the Zsgreen gene and either the RNAi control or RNAi Mus TS
sequence located between the ultramir 3’ and 5’ regions.
.

assess the activation of the OPN promoter. Activation of the OPN promoter was
accomplished by exposing cells to the systemic inflammatory stimuli LPS, the
inflammatory cytokines interferon gamma (INF-γ) and interleukin 1-β (IL-1β), or
condition media from cancer cell line CT26 that are thought to secrete molecules
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that are typically found in the tumor microenvironment. Microscopy and western
blot analysis shown in Figure 3.3 confirm an increase in visual and protein levels
of mCherry only in cells exposed to inflammatory stimuli INF-γ (b), LPS (c), IL1-β
(d), or conditioned media from CT26 cells (e). In addition, western blot analysis
quantifying mCherry protein levels confirm that protein levels of mCherry
increased after cells were exposed to the inflammatory stimuli. The results
indicated that regions -777 or -740 to +79 of the OPN promoter contain sites that
are responsive to inflammatory stimuli, thus permitting it to induce the expression
of the mCherry transcript as compared to the untreated cells (a). Western blot
analysis showed basal levels of mCherry expression in untreated cells, but at low
levels that will still allow the use of these promoter regions to drive the
expression an RNAi sequence against MusTS.
To further analyze these regions of the OPN promoter, we transduced
green fluorescent protein (GFP) expressing BMDCs with viral particles packaged
with these retroviral vectors. During transduction BMDCs were exposed to stem
cell factor (SCF), interleukin 3 (IL-3), and interleukin-6 (IL-6) cytokines and then
plated in methylcellulose to examine colony formation and the expression of
mCherry. Colony formation is conveyed in percentage wherein 100% of the
colonies formed in the control and the transduced BMDCs expressed GFP,
however transduced BMDCs expressing OPN (-777/-740 to +79) fused to GFP
showed that approximately 50% of the GFP colonies also expressed mCherry.
Figure 3.4 depicts the percentage of colony formation as well as the visual
confirmation of co-localization of GFP and mCherry expression in BMDCs. From
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LPS, IFN-γ, IL1-β
GP+E86 cells

MSCV

Puromycin

OPN-Pr

mCherry

MSCV

Figure 3.3: Inducible characteristic of the OPN promoter. Retroviral vector
containing OPN promoter region -740 to +79 driving the expression of a
mCherry reporter gene. A-E: GP+E86 cells stably transfected with the
retroviral vector in top panel were (A) untreated or treated with (B) IFN-ƴ, (C)
LPS, (D) IL1-β, (E) or conditioned media. (F): Western blot showing induction
of mCherry in response to the extracellular factors in A-E. Actin (*) was used
as an internal control for equal protein loading.

this ex vivo study, we are able to validate our ability to modulate the expression
of BMDCs, and show that the regions -777/-740 to +79 of the OPN promoter is
responsive to inflammatory stimuli. These results also implied that genetically
modified BMDCs expressing OPN (-777 or -740 to +79) driving the expression of
mCherry can be used to reconstitute irradiated mice since the growth of
progenitor colonies showed that transduction did not affect the ability of the
BMDCs to proliferate and differentiate. In addition, these results suggest that
reconstitution with the modulated BMDCs will allow us to visually examine the
activation of the OPN promoter by locating the expression of mCherry. Since, we
have only observed activation of the OPN promoter in the presence of
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inflammatory stimuli; these results indicate that expression of the mCherry
protein should only occur in an inflammatory environment such as tumor regions.

3.4.3 Validating reconstitution of irradiated ApcMin/+ mice with modulate
BMDCs
To observe BMDCs expressing OPN (-777/-740) promoters controlling the
expressing of mCherry in an in vivo model, we lethally irradiated existing BMDCs
from ApcMin/+ mice. Six week post transplantation genomic DNA was extracted
from the blood of mice and PCR amplified to confirm reconstitution with modulate
BMDCs. Amplification of genomic DNA for mCherry expression concluded that
we succeed in integrating the vector into the genome of mice (Figure 3.5);
however the expression of mCherry needed validation. Thus, we sacrificed
reconstituted mice to observe expression of mCherry within circulating BMDCs
from the blood and in the bone marrow compartment by flow cytometry analysis.
Even though, transduced BMDCs express GFP, we use antibodies against CD45
for a leukocyte cell surface- marker. Flow analysis of the circulating BMDCs in
the blood show that approximately 25% or 4% of the modulate BMDCs express
mCherry driven by OPN promoter -740 or -777 to +79 respectively (Figure 3.6a).
An increase expressing of mCherry was observe in the bone marrow
compartments, showing approximately 40% and 10% for OPN promoter -740 or 777 to +79 respectively (Figure 3.6b). The expression of mCherry in the mice
show that the OPN promoter is functional, and since less than 50% of the
transduced BMDCs are expressing mCherry in the blood and in the bone marrow
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Figure 3.4: Colony formation of modulate BMDCs expressing MSCV-OPN-mCherry vector. a. Percentage of GFP
colonies that were transduced with either OPN (740/777) - mCherry retroviral particles. 50% of the GFP colonies expressed
mCherry that were transduced with OPN (740)-mCherry viral particles, and approximately less than 50% GFP colonies
expressed mCherry that were transduced with OPN (777)-mCherry viral particles. b. Confocal microscopy images of
methylcellulose colonies displaying separately the expression of GFP or mCherry, and the merged co-localization expression
of GFP and mCherry (yellow).

compartment these results could be basal levels of OPN promoter activation, or
the promoter response to systemic inflammation. This basal level of OPN
promoter activation and mCherry expression may be problematic, for basal
activities may cause a systemic effect when driving the expression of an RNAi
sequence. It is essential that we determine which organs are infiltrated with
modulated BMDCs.

This will allow us to assess the basal activity of OPN

promoter and determine the possibility of systemic disadvantageous for future in
vivo assays with the addition of an RNAi sequence. In addition, we expected to

C57BL/6UB1-GFP

Genetic
modulation of
BMDCs

Apcmin/+
recipient

Figure 3.5: Confirming incorporation of MSCV-OPN-mCherry vectors
in vivo. a. Depiction of extracting BMDCs from donor C57BL/6-GFP
expression mouse to genetically modulate the cells with retroviral particles
to express mCherry to transplant into lethally irradiate APCMin/+ mice
recipients. b. Confirmation of successful reconstitution of transduced
BMDCs into recipient mice by PCR amplifying genomic DNA to detect
mCherry gene.

observe basal activity of OPN promoter activation in tumor burden mice, for
these mice are prone to more inflammation.
However if the expression of mCherry is not localized only in the tumor of
ApcMin/+ mice, the goal of tissue specific chemo- sensitivity will be impossible to
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accomplish by using the OPN promoter. Since, we observed a greater increase
of mCherry expression driven by OPN promoter (-740 to +79) region we only
evaluated this region of promoter in tissue sections. Rationing that this region
was to drive the expression of an RNAi sequence will cause the most harm
systemically, since until now both promoter regions behave similar.
3.4.4 Examining activation of the OPN promoter in tissues of ApcMin/+ mice
To determine if activation of the OPN promoter and expression of mCherry
in the ApcMin/+mice various tissue samples, such as the spleen,

liver, lung,

normal and tumor intestinal regions were collected to be analyzed by confocal
microscope. Confocal microscope allows us to examine the expression of GFP
and mCherry. Visual confirmation of GFP confirmed the infiltration of BMDCs
within different tissue, and the visualization of mCherry expression in tissues
provided confirmation of the OPN promoter activity. Co-localization of GFP and
mCherry expression view by yellow shows that infiltrated transduced BMDCs in
specific tissue is responsive to inflammatory stimuli. Our, previous data imply that
OPN is only induced by inflammatory stimuli, thus mCherry expression should
only be observed in the tumor regions the intestines of ApcMin/+ mice. Figure 3.5
examining the various tissue section from control and experimental mice by
confocal depicts images of the normal intestine regions, liver, and lung showing
negative expression of mCherry in these tissues. Spleen tissue images show
fluorescent background, yet we did not observe co-localization of mCherry and
GFP expressions. On the other hand confocal images of the tumor regions in
mice reconstituted with modified bone marrow show positive expression of
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mCherry when compared with the control. We observe co-localization of GFP
and mCherry expression only in the tumor regions of experimental group and not
in control group tumor (Figure 3.6). This compelling data from confocal
microscopy confirms that the OPN promoter is only induce in inflammatory

Figure 3.6: Flow analysis of transduced BMDCs expressing MSCV-OPN-mCherry
vector. a. Approximation of the percentage of transduced BMDCs that expressed either
OPN (740/777) - mCherry in the circulation of APCMin/+ mice recipient from flow
cytometry analysis. b. Approximation of the percentage of transduced BMDCs that
expressed either OPN (740/777) - mCherry in the bone marrow compartment of APCMin/+
mice recipient from flow cytometry analysis.

environment, for the expression of the mCherry was only observed in the tumor
regions and nowhere else in the animal. This data validates that OPN promoter
regions (-777/-740 to +79) will permit the ability to only chemo-sensitized the
tumor microenvironment, but only if these regions of promoter are able to drive
the expression of an RNAi sequence.
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Figure 3.7: Confocal microscopy analysis of the OPN promoter activity in various tissues. Confocal images of tissues sections
extracted from normal regions of the intestine, spleen, liver, and lungs of APCMin/+ mice recipient. The nucleus stained by Dapi (blue),
infiltration of BMDCs(green), expression of mCherry from BMDCs transduced with OPN(740)-mCherry (red), and co-localization
(yellow). Infiltration of BMDCs occurred in both the normal intestinal and spleen tissues. Co-localization expression of GFP and
mCherry was not observed in any tissue sections.
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Figure 3.8: Confocal microscopy analysis of the OPN promoter activity in the tumor region. Confocal images of tissues sections
extracted from the tumor regions of the intestine of APCMin/+ mice recipient. The nucleus stained by Dapi (blue), infiltration of
BMDCs(green), expression of mCherry from BMDCs transduced with OPN(740)-mCherry (red), and co-localization (yellow). Infiltration
of BMDCs occurred in the tumor intestinal tissues. Co-localization expression of GFP and mCherry was only observed in the tumor
section of recipients that were reconstituted with GFP BMDCs that were transduced to express OPN (740) – mCherry.

3.4.5 Ensuring OPN promoter aptitude to drive the expression of RNAi
sequence against MusTS
We have shown that the OPN promoter (-777/-740 to +79) can drive the
expression of the mCherry gene, but it is important to show that it has the
capacity to drive the expression of an RNAi sequence. Initially, we used the
pMSCV retroviral vector in which we inserted an RNAi sequence against MusTS
between the OPN promoter region and the mCherry transcript. An internal
ribosome entry site placed between the RNAi sequence and the mCherry gene to
ensure transcription of both. We established stable expression in cell lines
GP+E86 and CHL (MUS TS) in which cells treated in the presence or absence of
inflammatory stimuli to observe reduction of Mus TS protein levels. Unfortunately,
we were unable to observe a reduction in Mus TS protein levels (data not
shown). To determine if these results were correct or if there is a problem with
the construction of the vector design, we decided to evaluate the OPN promoter
in the pZip lenti-viral vector. To accomplish this we removed the existing the
mCMV promoter and replace it with the OPN (-740 to +79) promoter to drive,
such that OPN promoter would drive the expression of Zsgreen and the RNAi
sequence against MusTS. When stably expressed in CHL (Mus TS) cells, we
observed an appropriate phenotype. Proteins levels of Mus TS were reduce by
approximately 50% when compared to control and the vector control cells (Figure
3.9a/b). Demonstrating that the OPN promoter does has the potential to drive the
expression of an RNAi sequence. Since the OPN promoter reduces protein
levels, better than the mCMV promoter we need to analyze if this percentage of
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reduction effected cell proliferation. Performing a growth assay, we show that
cells expressing the RNAi sequence against MusTS, growth rate is not retarded

b.
a.

c.

d.

Figure 3.9: Examining the ability of the OPN promoter to control an RNAi
sequence. a. Western blot analysis of CHL (Mus TS) stably transfected with pZip lentiviral vector expressing either shRNA sequence or the vector control. Reduction of Mus
TS protein is only observed in cells transduced with the silencing sequence. b.
Quantification of the Mus TS protein shows the shRNA sequence reduces the
expression of Mus TS protein by approximately 50%. c. Growth curve graph indicating
that the growth rate of cells expressing the shRNA sequence is comparable to control
cells or the cells expressing the vector control. d. Growth inhibition assay show that
pZip vectors exhibit sensitivity to 5-FU therapy.

when compared to control cells or cells expressing the vector control (Figure
3.9c). Next we examine the ability of the OPN promoter to enhance sensitivity to
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5-FU by treating cells that expressed either the pZip-OPN-shRNA or pZip-OPN
control vector with increasing concentration of 5-FU to observe growth inhibition.
Cells that were not transfected with either of the pZip vectors was used as an
addition control to confirm that the vector control does not affect cellular
response to 5-FU. Results indicate that cells that are expressing the RNAi

Figure 3.10: Examining Zsgreen expression a. Microscopy images of cells
transduced to express pZip-OPN-vector and pZip-OPN-shRNA vector to observe
Zsgreen expression in cells. b. Flow cytometry analysis of cells transduced to
express pZip-OPN-vector and pZip-OPN-shRNA vector to quantify Zsgreen
expression in cells. c. Western blot analysis to quantify protein expression of
Zsgreen in transduced cells.

sequence against MusTS under the control of the OPN promoter are more
sensitive to 5-FU therapy in comparison to the vector control and control cells
79

(Figure 3.9d). These premises further assure the advantage in using the OPN
promoter to establish tissue specific chemo-sensitivity and drive the expression
of RNAi technology.
Additional, we determine that the expression of the RNAi sequence does
not corresponds to the expression of Zsgreen fluorescent marker under the
control of the OPN promoter. With microscopy and flow cytometry analysis, we
show that cells transduce to expression pZip-OPN vector control has a higher
percentage of cells expression Zsgreen compared to cell transduce to express
the pZip-OPN-shRNA vector (Figure 3.10a and b). Indicating that some cells in
the pZip-OPN-shRNA group expresses the shRNA sequence, however the
Zsgreen marker is silent. Results show that approximately 78% of the cells
transduced to express pZip-OPN vector expressing the Zsgreen fluorescent
protein, however only approximately 48% of the cells transduced to express the
pZip-OPN-shRNA vector expresses the Zsgreen fluorescent protein. The
expressing of the Zgreen protein in almost half expressed in the cell that were
are expressing the RNAi sequence against MusTS, however most importantly
these cells have been shown to be highly sensitivity to 5-FU treatment. This is
significant result because this demonstrates that cells do not have to express
Zsgreen to be more sensitive to 5-FU therapy.
3.4.6 Examining the apoptotic indices of modulate CHLT (MusTS) cells
To determine if we were able to enhance apoptosis in cells expressing the
pZip-OPN-shRNA vector in comparison to the controls we treated the cells with
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500nM or 10000nM of 5-FU for 5 days. These two concentration were used
because 500nM of 5-FU is the concentration to 5-FU needed to inhibit 50% cell
growth in cell expressing the pZip-OPN-shRNA vector previously shown in Figure
3.9c; and 10000nM of 5-FU was used because this concentration would ensure
that we would observe apoptosis in cells. We decided to use flow cytometry
analysis staining cells with Annexin V and viability dye antibodies. Using both of
these antibodies together, we were able to obtain late apoptotic indices (Annexin
V and viability dye positive cells) and early apoptotic indices (Annexin V only
positive cells). In addition, we were able to determine the apoptotic indices of
Zsgreen cells by identifying cells that express Zsgreen and Annexin V antibodies.
The result from this study are displayed in fold changes comparing the no treated
cells with the cells treated with either 500nm or 10000nM of 5-FU. For the late
apoptotic indices we observe a 0.5, 0.2, and 0.7 fold change increase in cells
treated with 500nM 5-FU for CHLT (Mus TS) control cells, cells transduced with
pZIP-OPN vector control, and cells transduces to express pZip-OPN-shRNA
vector respectively. The major fold change increase for late apoptotic indices
occurred when cells were exposed to 10000nM 5-FU. These fold change
increase are 5.0, 2.2, and 4.7 for CHLT (Mus TS) control cells, cells transduced
with pZIP-OPN vector control, and cells transduced to express pZip-OPN-shRNA
vector respectively (Figure 3.11a). Even though, we did not observe a
significance in the apoptotic indices for late apoptosis we do indeed observe a
significant difference in the early apoptotic indices in cells treated with the highest
concentration of 5-FU. Results show increase fold changes of 26.1, 20.7, and
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59.7 for CHLT (Mus TS) control cells, cells transduced with pZIP-OPN vector
control, and cells transduced to express pZip-OPN-shRNA vector respectively
(Figure 3.11b). These results show that cells transduced to express the pZipOPN-shRNA vectors are highly apoptotic compared to the control, Thus
confirming the RNAi sequence against MusTS is enhancing cellular sensitivity to

Figure 3.11: Apoptotic indices of transduce CHLT (MusTS) cells. a. The late
apoptotic indices of cells treat with 5-FU. b. The early apoptotic indices of cells
treated with 5-FU. c. The apoptotic indices of cells expressing Zsgreen. d. Western
blot analysis of Parp-1 protein expressing from cells treated in the absence or
present of 500nM of 5-FU.

5-FU. Upon, investigating the apoptotic indices in Zsgreen expressing cells
results also show that cells expressing the RNAi sequences are highly more
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apoptotic than cells that are expressing on the vector control. The fold change
increase are 17.2 and 50.6 for pZip-OPN- vector control and pZip-OPN-shRNA
vector respectively (Figure 3.11c). In addition western blot analysis of Parp-1
protein expression show and increase in cells treated with 500nM 5-FU when
compared to cells that are not expose to the drug (Figure 3.11d). The premise of
these finding confirms the ability to establish chemo-sensitivity within the TME.
3.4.7 Examining the apoptotic and proliferation indices of modulate BMDCs
in Balb/c CT26 subcutaneous tumor model
To evaluate if the tissue specific chemo-sensitivity can be achieved by
using the OPN promoter we performed an acute study which involve lethally
irradiated Balb/c mice and reconstituted with BMDCs that expressed the pZip
vector that contain Zsgreen and TS RNAi sequence driven by the OPN (-740 to
+79) promoter. Controls for this study were Balb/c mice reconstituted with
BMDCs that expressed the vector control that contain the Zsgreen gene under
the control of the OPN promoter or GFP BMDCs. Four weeks post reconstitution
mice with modulated BMDCs; genomic DNA was extracted from the blood to
confirm incorporation of the Zsgreen gene in the genome (Figure 3.12). Six
weeks post reconstitution CT26 colon cancer cells was injected in the flank of
these mice. Tumors were allowed to grow to approximate 10-12mm diameter
before mice were subjected to a single i.p. injection of either PBS or 50mg/kg 5FU. Tumors average growth rates shown in Figure 3.12. We did not observe
significant reduction in the growth of tumors in the experimental groups in
comparison with the controls, which is expected since mice were only exposed to
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a single injection of 50mg/ kg of 5-FU. Five days post therapy mice were
sacrificed to collect the tumor for flow analysis to determine apoptotic and
proliferation indexes in CD45+ immune cells, T cytotoxic cells (CD8a/CD8b),
mast cells (CD34/CD117), MDSCs (Gr1/CD11b), and T regulatory cells

Figure 3.12: Confirming incorporation of pZip-OPN lenti-viral vectors in
vivo. a. Confirmation of successful reconstitution of transduce BMDCs into
recipient mice by PCR amplifying genomic DNA for the incorporation of the
Zsgreen and either the RNAi control or RNAi Mus TS sequence located
between the ultramir 3’ and 5’ regions from the pZip-OPN control vector or of
pZip-OPN-MusTS shRNA vector. b. CT26 cells tumor growth rate in mice
that were reconstituted with modulate BMDCs or control BMDCs.

(CD4/Foxp3). We decided to obtain data five days post therapy, for previous
result from our lab observed reduction in MDSCs, moderate effect in Tregs cells,
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and resistance in mast cells in the tumor bed of Balb/c mice in a time course
treatment study for ten days to observe BMDCs response to 5-FU in this
advance colorectal model. The quantity of MDSCs and Tregs within the CT26
tumor in Balb/c mice displayed a 0.5 fold change five day after a single dose of 5FU. Recovery for both these cells type were back to normalcy by day 7.
Conversely, mast cells displayed a two folds increase within the tumors five days
after 5-FU exposure and returned to basal level at day 7 (unpublished data
Acharya, Grishma). Using this prior data as the initial point of interest, we expect
to observe an enhancement in the reduction of MDSCs and Treg cells in
response to 5-FU, but most importantly we expect to observe sensitivity of tumor
mast cells to 5-FU in mice that are reconstituted with the genetically modulated
BMDCs. In addition to these three cell types we decide to observe the effects of
5-FU on CD45+ immune cells and cytotoxic T cells (Tc cells). Observing the
response of the broad spectrum of immune cells, in particular CD45+ cells may
provide a better depiction of the effect of 5-FU on BMDCs.

Additionally,

observing the effects of 5-FU on Tc cells will provide a depiction of how 5-FU
disrupts antitumor immunity activities, which are typically performed by these
cells.
Figure 3.13 represents the flow analysis, which provides the percentages
of cells that are positive for the surface markers to identify the different cell types.
In similarity with our previous acute time course study, we observed
approximately 10% reduction in the MDSCs cell population five day post 5-FU
subjection in the control and vector control groups when compared to the cohorts
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subjected to PBS. However, the percentage of tumor MDSCs increased
approximately 7% in mice transduced with BMDCs expressing the shRNA vector
and exposed to 5-FU compared to the mice transduced with BMDCs expressing
the shRNA vector and subjected to PBS (Figure 3.13a). Examination of the tumor
Tregs show an approximately 3%, 1.5%, and 2% increase in animals treated with
5-FU for control, OPN vector control, and OPN-shRNA vector groups
correspondingly compared to respective PBS animals (Figure 3.13b). Figure 3.13
c demonstrates an increase in tumor mast cells for the control and OPN-shRNA
vector groups, approximately 2% and 10% respectively. However, for the OPN
vector control and 5-FU treated mice, tumor mast cells were reduced
approximately 1.5%. Behaving similarly to Tregs we observed an increase of
tumor Tc cells in all groups, approximately 3%, 0.5%, and 5% for the control,
OPN vector control, and OPN-shRNA vector mice expose to therapy
correspondingly (Figure 3.13 d). Lastly, resembling the trend of tumor MDSCs we
observed reduction of tumor CD45+ immune cells in both the control and OPN
vector control 5-FU treated mice, approximately 16% and 5% respectively.
However, an approximately 20% increase occurred in mice transduced with
BMDCs expressing OPN-shRNA vector and treated with 5-FU compared to PBS
cohorts (Figure 3.13 e).
Advance, flow analysis permitted examination of the total apoptotic and
proliferation indices of each of these cell types. Additionally, the total apoptotic
and proliferation populations further evaluation is accomplish by dividing the
population into two subgroups: Zsgreen positive or Zsgreen negative apoptotic
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and proliferative populations, which are depicted by the percentages bar graphs
in Figures 3.14-3.18. The Zsgreen positive population identifies modulated
BMDCs expressing either the OPN vector control or the OPN-shRNA vector. The
double stained surface markers plus Zsgreen positive or Zsgreen negative
Detection of AnnexinV antibody determined the apoptotic index, and detection of
intercellular levels of ki67 determined the proliferation index for each target cell
types.
Firstly, examining the of total apoptotic index of tumor MDSCs show that
the percentage of apoptotic MDSCs decrease in the tumor of control mice treated
with 5-FU in comparison to the PBS cohorts, however the apoptotic percentages
of tumor MDSCs in mice reconstituted with transduced BMDCs expressing either
lenti-viral vectors display an increase of apoptotic tumor MDSCs. There is a 3%
and 16.8% increase of apoptotic tumor MDSCs in mice subjected to 5-FU in OPN
vector or OPN-shRNA vector groups respectively, when compared to PBS
cohorts (Figure 3.14 a). Notably the proliferation of tumor MDSCs does not
decrease for any of the groups after 5-days post 5-FU treatment. The percentage
of proliferative MDSCs for the PBS and 5-FU cohorts in the control group are
similar; and a proliferative increase of a 4.4% and 17.5% occurred in OPN vector
control and OPN-shRNA vector - 5-FU treated animals respectively, paralleled to
PBS cohorts (Figure 3.14 b). Only for the 5-FU control group was there a 4.6%
increase in the percentage of tumor Tregs, and no change in the percentage of
proliferative tumor Tregs for this group when equated to control PBS mice. Yet
there was a slight decrease of 1.5% or no variation in the percentage of apoptotic
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Tregs in OPN vector control or OPN-shRNA vector reconstituted animals treated
with 5-FU, however the proliferative percentage of Tregs does increase by 9% or
3.8% for each respective groups compared to PBS mice (Figure 3.15).
Highlighting that the percentage of apoptotic tumor mast cells only displayed a
percentage increased in mice reconstituted with BMDCs expressing the OPNshRNA vector and treated with 5-FU by 2.6% elevation compared to the PBS
cohorts. The other 5-FU treated mice for control and the OPN-vector control
showed a decreased in the percentage of apoptotic tumor mast cells when
compared to PBS associates. However, an increase in the total percentage of
proliferative tumor mast cells occurred in OPN vector control and OPN-shRNA
vector groups that were exposed to 5-FU, whereas a reduction was seen in the
control 5-FU group ( Figure 3. 16). Observing the percentage of tumor apoptotic
Tc cells result show a decrease for both control and OPN vector control, 3.6%
and 7.4% reduction respectively, however, result show an increase of 12.5% for
the

OPN-shRNA

vector

reconstituted

animals

when

equated

to

the

corresponding PBS treated mice. All groups displayed a reduction in the
percentage of tumor proliferative Tc cells (Figure 3.17). Lastly, examining the
percentage of apoptotic CD45+ immune cells in the tumor after 5-FU treatment
show an increase for all groups compared to the PBS treat animals. The increase
of apoptotic CD45+ immune cells is 0.5%, 1.2%, and 9.7% for control, OPN
vector control, and OPN-shRNA vector 5-FU treated mice respectively. Only the
proliferative percentage for CD45+ immune cells increased by 15.2% for mice
reconstituted with BMDCs expressing the OPN-shRNA vector and subjected to
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5-FU, whereas the decrease in the percentage of proliferative CD45+ immune
cells was observed in the control and OPN-vector control 5-FU subject mice
compared to PBS counterparts ( Figure 3.18).
Advance analysis of the apoptotic and proliferative indices of each cell
types by dividing the total percentage of indices into subgroups dependent on
present or absent of Zsgreen expressing will indicate if modulate BMDCs
expressing the shRNA sequence is more sensitive to 5-FU therapy. It is
important to note that expression of Zsgreen does not determine correlate with
expression of the shRNA sequence against TS. For we did not determine the
difference of expression of TS protein levels in Zsgreen or non-Zsgreen cell
types. Thus, briefly examining the of apoptotic indices of MDSCs, mast cells,
Tregs cells, and Tc cells that are Zsgreen positive result show no increase the
percentage of apoptotic cells after 5-FU treatment compared to PBS. However,
examining the non-Zsgreen cells of each of these cell types that are transduced
to express the shRNA show an increase in the apoptotic indices compared to the
PBS group, thus suggesting the shRNA may be expressed in some of the nonZsgreen cells and thus enhance cellular sensitivity to 5-FU treatment. Also, to
confirm this implication analyzing the result for the CD45+ immune cells
modulated to express OPN-shRNA vector, result shows that in both subgroups
Zsgreen positive and negative cells after 5-FU therapy increases the percentage
of apoptotic CD45+ immune cells equated to the PBS treated cohorts.
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Figure 3.13: Flow analysis of tumor BMDCs populations. a. The total percentage of tumor MDSCs double stained with
CD11b and Gr1 antibodies. b. The total percentage of tumor regulatory T cells stained with CD4 and Foxp3 antibodies. c. The
total percentage of tumor mast cells stained with CD34 and CD117 antibodies. d. The total percentage of tumor cytotoxic T
cells stained with CD8a and CD8b antibodies. e. The total percentage of CD45+ immune cells stained with CD45 antibody.
Each graph include mice reconstituted with non- transduce BMDCs (Control), or mice reconstituted with BMDCs expressing
either the OPN- vector control (OPN), or OPN-shRNA vector (OPN-shRNA). Each of these engraftment groups are subdivided
into two groups of animals either exposed to PBS for the control or to 50mg/kg of 5-FU for the treatment and experimental
group.
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Figure 3.14: Apoptotic and proliferation indices for tumor MDSCs. a. The apoptotic indices of tumor MDSCs for mice either
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPNshRNA vector (OPN-shRNA). b. The proliferative indices of tumor MDSCs for mice either reconstituted with non-transduced
BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice
reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.
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Figure 3.15: Apoptotic and proliferation indices for tumor Tregs cells. a. The apoptotic indices of tumor Tregs cells for mice either
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPNshRNA vector (OPN-shRNA). b. The proliferative indices of tumor Tregs cells for mice either reconstituted with non-transduced
BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice
reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.
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Figure 3.16: Apoptotic and proliferation indices for tumor mast cells a. The apoptotic indices of tumor mast cells for mice
either reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or
OPN-shRNA vector (OPN-shRNA). b. The proliferative indices of tumor mast cells for mice either reconstituted with nontransduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPNshRNA). Mice reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.
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Figure 3.17: Apoptotic and proliferation indices for tumor Tc cells. a. The apoptotic indices of tumor Tc cells for mice either
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPNshRNA vector (OPN-shRNA). b. The proliferative indices of tumor Tc cells for mice either reconstituted with non-transduced BMDCs
(Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPN-shRNA vector (OPN-shRNA). Mice reconstituted
with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.
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Figure 3.18: Apoptotic and proliferation indices for CD45+ immune cells. a. The apoptotic indices of tumor CD45+ immune
cells for mice either reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector
control (OPN) or OPN-shRNA vector (OPN-shRNA). b. The proliferative indices of tumor CD45+ immune cells for mice either
reconstituted with non-transduced BMDCs (Control) or modulated BMDCs expressing either OPN-vector control (OPN) or OPNshRNA vector (OPN-shRNA). Mice reconstituted with the various BMDCs were either subjected to PBS or 50mg/kg of 5-FU.

Since, the percentages of apoptotic cells were higher than expected from the
flow analysis. We further analyze the apoptotic indices of some cells by confocal
imagery. Unlike flow analysis, we were unable to stain with two surface markers
to identify the different cell types.

Thus, for MDSCs we stained for both

granulocytes and monocytes by using antibodies against surface markers Ly-6
and Cd11b respectively, antibodies against surface marker c-kit was used to
identify mast cells, and to determine the apoptotic cells we stained with cleaved
PARP-1. Thus, the combination of one surface marker and cPARP-1 antibodies
were used to determine the apoptotic indices of Ly-6 positive granulocyte, CD11b
positive monocytes, and c-kit positive mast cells. The apoptotic indices for each
of these cells are express by the percentage of the cells stained positive for both
the surface marker and a cPARP-1 antibody, which was accomplished by
counting 100 field views for each cell type, and PBS treated mice, were used to
determine apoptotic baseline of each cell type. Figure 3.19 shows the apoptotic
indices for Ly-6 cells, and results show that 5-FU treated mice apoptotic indices
increases approximately 6% and 14% for mice reconstituted with BMDCs
transduce to express pZip-OPN vector control or pZip-OPN-shRNA vector
respectively. This same trend is observed in CD11b positive cells showing
approximately an 8% and 17% increase (Figure 3.20), and for c-kit positive cells
showing approximately, a 3% and 7% increase for mice treated with 5-FU and
engrafted with modulate BMDCs (Figure 3.21). In comparing 5-FU, treated
animals we show that mice engrafted with BMDCs expressing the shRNA vector
had more apoptotic monocytes, granulocytes, and mast cells.
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Even though,

these are promising results, we were unable to determine which of the Ly6,
CD11b, and c-Kit positive cells were transduced to express either the pZip-OPN
vector control or the pZip-OPN-shRNA vector. Due to the inability to distinguish
the real signal of Zsgreen in the Fittc channel from the confocal microscopy
analysis, we are unable to quantify the number of cells that are transduced.
Therefore, are unable to determine if the transduced cells expressing the RNAi
sequence are highly apoptotic cells when compared to the controls. However, we
are able to infer this data by combining results from our flow analysis with our
results from our confocal microscopy analysis. From our flow analysis, we are
able to determine the percentage of cells that are positive for both Zsgreen and
MDSC or mast cell markers, and by using this percentage has a reference to
infer the percentage of Ly6, CD11b, or c-Kits positive stained cells from confocal
microscopy analysis which maybe Zsgreen. Theoretically, this is logically since
these are the same tumors samples for both flow and confocal microscopy
analysis. These inference results in Figure 3.22 show the difference between
cells transduced to express the pZip-OPN vector control and the pZip-OPNshRNA vector. Results show that Zsgreen Ly6 positive cells treated with 5-FU
has either

a 5% or 11% increase in mice engrafted with BMDCs expressing

pZip-OPN vector control or pZip-OPN-shRNA vector respectively (Figure 3.22a).
Figure 3.22 b and c show the same trend observed in Zsgreen CD11b
demonstrated a 7% or 13% increase, and for Zsgreen c-Kit positive cells a 0% or
5% increase for samples that expressed the pZip-oPN vector control or the pZipOPN-shRNA vector respectively.

.
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Figure 3.19: Apoptosis induced in granulocytes at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c
mice were stained with rat monoclonal primary antibody againstLy-6 and rabbit polyclonal primary antibody against c-PARP-1. The
samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit
secondary antibody, respectively. 100 total images were taken for both PBS and 5-FU samples... a. Representative field views of
confocal images of tumor sections from PBS and 5-FU treated mice are shown. Green = Gr-1 positive cells (granulocytes), Red =
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic granulocytes. b. Percentage of apoptotic Ly-6 cells in the
tumor tissues of mice reconstituted with modulated BMDCs.

a.

b.

OPN-ScrRNA

99

OPN-MusTS
shRNA

Figure 3.20: Apoptosis induced in monocytes at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c
mice were stained with rat monoclonal primary antibody againstCD11b and rabbit polyclonal primary antibody against c-PARP-1.
The samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit
secondary antibody, respectively. 100 total images were taken for bothPBS and 5-FU samples. .a. Representative field views of
confocal images of tumor sections from PBS or 5-FU treated mice are shown. Green = CD11b positive cells (granulocytes), Red =
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic monocytes. b. Percentage of apoptotic CD11b cells in
the tumor tissues of mice reconstituted with modulated BMDCs
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Figure 3.21: Apoptosis induced in mast cells at 5 days after 5-FU administration. Tumor tissues from reconstituted Balb/c
mice were stained with rat monoclonal primary antibody against c-Kit and rabbit polyclonal primary antibody against c-PARP-1. The
samples were then incubated with Cy-3-conjugated donkey anti-rat secondary antibody and Cy5-conjugated donkey anti-rabbit
secondary antibody, respectively. 100 total images were taken for both PBS and 5-FU samples. a. Representative field views of
confocal images of tumor sections from PBS or 5-FU treated mice are shown. Green = c-kit positive cells (mast cells), Red =
cleaved PARP-1 (apoptotic cells). Double positive cells indicate apoptotic monocytes. b. Percentage of apoptotic c-kit cells in the
tumor tissues of mice reconstituted with modulated BMDCs
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Figure 3.22: Theoretical apoptotic indices of modulate BMDCs expressing Zsgreen. This data is theoretical data from flow
cytometry analysis taking the percentage of positive Zsgreen cells to determine the number of cell of positively stained cell by
confocal analysis is Zsgreen positive. a. Theoretical percentages of apoptotic indices of Zsgreen and Ly6 positive cells from 100
field views. b. Theoretical percentages of apoptotic indices of Zsgreen and CD11b positive cells from 100 field views. c. Theoretical
percentages of apoptotic indices of Zsgreen and c-Kit positive cells from 100 field views.

3.5

DISCUSSION:
To be able to establish tumor specific chemo-sensitivity to TS inhibitors it

was necessary to identify an RNAi vector system that does not exhibit cytotoxic
effect in vivo. For our previous studies, which used the retroviral pSuper vector to
establish constitutive expressing of a silencing sequence suggest we had the
ability to examine systemic effects reducing TS protein levels in vivo. However,
introduction of transduce BMDCs expressing this RNAi system in ApcMin/+ mice
demonstrated detrimental results, in that none of the mice survived engraftment.
The effects from our prior result points out the importance of identifying an RNAi
vector system that has the capacity to be used for in vivo studies. Therefore, we
decided to employ the pZip-mCMV lenti-viral RNAi vector system, for this system
contains resemblance characteristics of endogenous pri-miRNA. Mechanistically
allowing the embedded shRNA to be processed by endogenous RNA-induced
silencing complex. Additionally, this system uses the polymerase II promoter
mCMV to control the expression of the shRNA, permitting the ability to observe in
vivo systemic effects cause by the reduction of TS protein levels. Result from this
study confirms that the mCMV promoter does have the capacity to control and
RNAi sequence to suppress the expression of TS protein levels in vitro.
However, does not have the ability to reduce protein levels enough to establish
or enhance sensitivity to 5-FU displays by our growth inhibition assay results.
Despite this system inability to enhance sensitivity in vitro, it is essential to
investigate its potential of introduction into an in vivo cancer model. Indeed,
results confirmed that transduced BMDCs expressing this vector system could be
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introduced into lethally irradiated Balb/c mice without exhibiting any cytotoxic
effect to the mice. Since in vitro studies were unsuccessfully in providing
enhance sensitivity to therapy, we presume the same result would occurred in
vivo. Conversely, we succeeded in identifying an RNAi vector system that
exhibits the capacity to modulate BMDCs by lessen the expression of cellular TS
for in vivo studies.
Thus, proceeding forward to enhance cellular response to tumor specific
TS target therapy we decided to examine the functionality and aptitude of the
OPN promoter.

Prior studies by Denhardt and colleagues examined and

investigated regions within the promoter that contain enhancers that are
responsive to pro-inflammatory stimuli. Exploiting the inducible characteristic of
the OPN promoter, we elect to use this promoter to establish tumor specific
chemo-sensitivity. Nonetheless, before using this promoter to establish sensitivity
it was necessary to determine if this promoter functionality would only be active
within the TME; and indeed our results demonstrated that

expression of

mCherry protein driven by region -740 to +79 of the OPN promoter was only
located in the tumor regions of intestinal tissues of ApcMin/+

mice. Confirming

activation of the OPN promoter only occurred within the tumor regions was
essential for our strategy to achieve tumor specific chemo-sensitivity.
As important to determine the functionality of the OPN promoter, it was
also necessary to determine its aptitude to drive the expression of the RNAi
silencing sequence against TS. Thus, to investigate OPN promoter potential we
elected to use the pZip-lenti-viral RNAi vector system, for which the OPN
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promoter replaces the mCMV promoter. Our result illustrates OPN promoter
ability to control the expression of a silencing sequence, and is able to establish
significant reduction of cellular MusTS cellular unlike the mCMV promoter.

In

addition, we were able to establish enhance cellular sensitivity with the OPN
promoter controlling the expression of TS silencing sequence, and so we
acquired all the essential components to modulate BMDCs, such to investigate
the ability to enhance efficacy of therapy within in the TME.
Although, we have the necessary components to establish tumor specific
chemo-sensitivity our approach demonstrates inadequacies and the need for
revisions in order to observe the optimal effects of this particularly therapy. For
we successfully modulate BMDCs to express pZip-OPN vectors in a
subcutaneous cancer mouse model, however the verdict of established tumor
specific chemo-sensitivity to 5-FU needs further investigation and evidence. To
begin we decide to use flow cytometry analysis to determine the difference of
apoptotic indices for MDSCs, mast cells, Tregs, Tc cells, and CD45+ immune
cells. However, the percentage of apoptotic cells for each cell types is rather high
than expected for the PBS treated mice, thus comparing the effect of 5-FU was
difficult to determine. A possible explanation for such high apoptotic percentages
could be, due to the multiple step staining procedures need to identify each cell
types apoptotic indices.

In the samples, processing the integrity of the cell

membrane may have been disturbed, causing higher percentages of apoptotic
cell populations.
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On the other hand, examining the total proliferative indices of cell types
MDSCs, Tregs cells, mast cells, and CD45+ immune cells results show an
increase in proliferation after subject to 5-FU in BMDCs expressing the OPNshRNA vector. These results are alarming for expected results should display a
decrease in proliferation within these cells type in comparison to the PBS treated
mice. A possible explanation is that these results are illustrating residual
response of 5-FU treatment, such that the system is attempting to recover from
5-FU effects by increase the proliferation.
The results from our flow analysis study did not provide any clear
indication that we have accomplished tumor specific chemo-sensitivity, for our
initially had approach flaws. For this, we decided to examine the apoptotic
indices of MDSCs subgroups granulocytes and monocytes cells and mast cells
by confocal analysis. For MDSCs are highly responsive to 5-FU therapy and
mast cells exhibits minimal to no responsiveness to 5-FU therapy, and thus by
examining these cells types we would be able to determine if we establish
specific chemo-sensitivity and enhance the efficacy of 5-FU therapy within the
TME. Our results demonstrate an increase in apoptotic indices for granulocytes,
monocytes, and mast cells in 5-FU treated mice when compared to respective
PBS treated mice. Most importantly, we observed higher apoptotic indices in
mice reconstituted with BMDCs expressing the pZip-OPN-shRNA vector than
with pZip-OPN vector control. This is promising data because we demonstrate
the ability to enhance the efficacy of 5-FU within the TME of an in vivo cancer
model. Unfortunately, with our confocal microscopy analysis we were unable to
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distinguish which of the positive stained cells expressed the pZip vectors, for we
were unable to determine the real signal of Zsgreen expression in the FITTC
channel due to auto-fluorescent background signaling. Alternatively, we
attempted to stain for Zsgreen with antibodies to quantify the number of cells
triple positive (surface marker, apoptotic marker, and Zsgreen positive), however,
there was only one antibody against Zsgreen on the market, and it did not
successfully work for staining, for it known applications were for western blot and
immunoprecipitation analysis. Such that we decide to theoretically, conclude our
results from the animal studies by using data from both our flow cytometry and
confocal microscopy studies. In theory, the same tissue samples used for both
studies; therefore, the percentage of Zsgreen cells determined from the flow
cytometry analysis is the same percentage of positive cells for the confocal
analysis. Using these percentages, we were able to theoretically inference the
percentage of Ly6, CD11b, or c-Kit positively stained cells that are also Zsgreen
positive. From these results, again we were able to inference that mice
reconstituted with BMDCs expressing the pZip-OPN-shRNA vector had a higher
apoptotic indices than mice reconstituted with BMDCs expressing the vector
control.
Even though, our confocal microscopy and theoretical results are
promising, the results were not significant. Possible reasoning is that mice were
reconstituted with twenty percent of modulated BMDCs. It is possible to enhance
sensitivity by reconstituting mice with either a higher percentage or 100% of
modulated BMDCs expressing the pZip-OPN-shRNA vector. Additionally, it is
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necessary to determine if the Zsgreen expression correlates with shRNA
expression, to accomplish this, transduced BMDCs needs to sorting into two
populations Zsgreen positive and negative, such to measure and compare the
differences of mRNA and/ or protein in the two populations. These results will
provide a better depiction of the expression of the shRNA. Importantly, to
examine the ability to enhance the effect of 5-FU therapy more acute studies are
necessary at different time points post therapy to gain and assess the overall
response of genetic modulate BMDCs to 5-FU therapy.
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CHAPTER 4

THE EFFECTS OF MAST CELL INHIBITION ON TUMOR RESPONSE IN
APCMIN/+ MICE

_____________________________
3

The Effects of Mast Cells Inhibition on Tumor Response to 5-FU in
ApcMin/+mice, Nikeya L. Tisdale, Celestia Davis, Maria Marjorette O. Peña.
To be submitted.
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4.1

ABSTRACT:
Mast cell precursors originate in the bone marrow and migrate through the

blood into tissues where terminal differentiation and maturation occurs. They are
essential for inflammatory stimuli, and when activated, release an array of
cytokines and molecules. In response to treatment with 5-fluoruracil (5-FU), an
inhibitor of the enzyme thymidylate synthase that is used in the clinical
management of colorectal cancer, we found that mast cells are recruited into the
tumor’s beds in ApcMin/+mice, where they may play a role in tumor recurrence
post therapy. Because of this, we examined the possibility that pharmacological
inhibition of mast cells might play a synergistic role when combined with 5-FU.
The objective of this study is two-fold: 1) to determine if pharmacological
inhibition of mast cells can interfere with tumor development, and 2) to determine
if mast cell inhibition can enhance the antitumor effects of 5-FU or prolong tumor
recurrence post therapy. ApcMin/+ mice were subjected to a regimen of 5-FU or
Cromolyn, a mast cell inhibitor, alone or in combination. Findings suggest that
inhibition of mast cells can influence tumor development, but has little impact on
tumor recurrence after therapy.

4.2

INTRODUCTION:
Tumors are complex organs consisting of a heterogeneous population of

both cancer and host-derived non-cancer cells interactions. These nonneoplastic cells compose the tumor stroma and play a critical role in tumor
initiation, progression, and response to therapy. Hence, effective anti-cancer
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therapies should target not only the tumor cells but also the non-tumor cells,
which may contribute to tumor resistance during therapy or its recurrence post
therapy.
Tumor recurrence or resistance to TS inhibitors has been a major problem
for many years. A previous study by Tucker et. al., systemically treated ApcMin/+
mice with 5-FU. Results showed reduction in tumor burden, yet when treatment
is ceased, tumor recovery is induced (Tucker, Davis et al. 2002). This result
could potentially be influence by the associate BMDC such as mast cells that
infiltrate or surround the tumor in a protective manner. In addition to this study
unpublished data from our lab showed that a single dose of 5-FU (50mg/kg)
administered to ApcMin/+ mice reduced the number of tumor associated MDSC
and regulatory T cells, but mast cells were still recruited to the tumor bed
(Acharya, unpublished data). Implicating, mast cells potential to be effector cells
that may influences tumor resistance and recurrence post 5-FU therapy.
Mast cells are effectors cells that play major role in inflammation, allergic
reactions, and wound healing mechanism. Their precursors are release from the
bone marrow compartment as immature cells, allowed to migrate into various
tissues within the body to undergo maturation and differentiation. Maturation and
differentiation is influence by the tissue environment for which infiltrated, resulting
in a heterogeneity population, which can be promising for the development of the
tumor, such that the TME can influence the maturation of the mast cells to assist
in tumor progression. Mast cell pro-tumor responses are dependent on the type
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of cancer and the stage of the tumor development (Groot Kormelink,
Abudukelimu et al. 2009; Ribatti 2013; Oldford and Marshall 2014)
Several studies have examining mast cells pro-tumorigenic role in mouse
models.

Gounaris

et

al.

have

shown

that

mast

cells

infiltrate

the

microenvironment of gastrointestinal polyps in three mouse models, which
include the ApcMin/+ mouse, and that mast cells are require and essential for the
initial stages of adenoma development (Gounaris, Erdman et al. 2007). Another,
study showed that performing adoptive transplant of naive Tregs from healthy
mice into APC∆468 mice reduces mastocytosis, resulting in a reduction of tumor
burden (Gounaris, Blatner et al. 2009). A study demonstrates that deletion of
mast cell 5-Lipoxgenase (5-LO), a pro-inflammatory mediator, proved to reduce
tumor numbers, resulting in the mitigation of MDSCs in the polyps of APC ∆468
mice (Cheon, Khazaie et al. 2011; Cheon, Strouch et al. 2012). These particular
studies, show that mast cells are associated with tumor development and
progression, and should be potential target when combating cancer.
One potential way to target the pro-tumorigenic functions of mast cells is
to inhibit mast cells degranulation by administering a pharmacological drug,
Cromolyn. Cromolyn is classified as a mast cell stabilizer that blocks mast cells
degranulation by indirect inhibition of the influx of calcium by blocking chloride
channels within the cells(Matthews, Neher et al. 1989; Norris and Alton 1996).
The exact mechanism of inhibition is poor understood. However, several studies
have administered Cromolyn to cancer mouse models and have observed
promising effects. A study, by Souceket.al indicates the mast cells infiltrates and
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assists with the expansion of Myc-induced pancreatic tumors. However, upon
inhibition of mast cell degranulation with Cromolyn resulted in reduction of tumor
islet expansion. (Soucek, Lawlor et al. 2007). Another, study subcanteously
injected well-differentiated prostate cell line into the flank of mice, to allow tumor
development. These mice were subjected to Cromolyn daily for three weeks, and
treatment with Cromolyn showed reduction or elimination tumor growth (Pittoni,
Tripodo et al. 2011). An additional study demonstrated that combining Cromolyn
with Gemcitabine, a drug typically used to treat pancreatic cancer, enhance the
effects of Gemcitabine to reduce tumor growth in pancreatic mouse models
(Arumugam, Ramachandran et al. 2006).
Since, mast cells are essential in tumor formation we postulate that the
inhibition of mast cell may reduce tumor counts as well as reduce the potential
recurrence post therapy. Thus, ideally utilizing a pharmacological drug such as,
Cromolyn that inhibits the degranulation of mast cells in combination with 5-FU
therapy should be beneficial to treat colon cancer. We sought to determine if
administration of Cromolyn post 5-FU therapy would hinder tumor development,
and prolong the anti-tumor effects of 5-FU therapy. Results indicates that a
synergistic effect does occur with the addition of Cromolyn post 5-FU therapy,
however, additional studies are necessary to analyze the mechanistic effects to
truly determines if this treatment has a prolong effect.
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4.3

MATERIALS AND METHODS:

Treatment Schedules
Six week old ApcMin/+ mice were subjected to systemic treatment with 5-FU
(40 mg/kg) for five weeks with one week intervals between three treatment
weeks. Mice treated with a combination of 5-FU and Cromolyn (10 mg/kg)

50 mg/kg 5-FU
(I.p. injections)
10mg/kg Cromolyn
(I.p. injections)

Figure 4.1: Mast cells chemotherapy regimen. Chemotherapy schedules for 5-FU,
Cromolyn, and 5-FU+ Cromolyn administration for the non – tumor recovery groups
(blue box), and for the tumor recovery groups (purple box). PBS (control group) is
administrated during the duration of the chemotherapy schedules.

determined the effect of mast cell inhibition on tumor burden, response to
therapy,

and

recurrence

post

therapy.

Illustrated

below

(Figure

4.1),

administering Cromolyn occurred in weeks 7 and 9, with 5-FU administered
during weeks 6, 8, and 10. The Cromolyn treatment then resumed for the 6
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weeks after the 5-FU therapy (Figure 4.1). Mice treated with PBS, Cromolyn, or
5-FU alone served as the controls.
Tissue collection, Tumor Scoring, and Granulocytes staining
ApcMin/+ mice were humanely sacrificed at the end of the treatments either
at 10 or at 16 weeks by cervical dislocation. Collecting the small intestines and
colon require cleaning by flushing with PBS, cutting open longitudinally, and
fixing in 4% paraformaldehyde overnight. This prepares the fixed tissues for
tumor scoring or histological analysis. For tumor, scoring fixed tissue requires
staining in 0.002% methylene blue in PBS pH 7.4 for visualization of the tumors
with a dissecting microscope. Tumors were classified as being greater or less
than 1mm in diameter with an ocular micrometer. For histological analysis fixed
tissues was Swiss-rolled and embedded in paraffin cassettes and left to dry
overnight.

Slices from the embedded paraffin cassettes (3-5 micron) form

sections, which are mounted on standard microscopy slides coated with poly-Llysine. The Instrumentation Resource Facility (University of South Carolina
School of Medicine) conducted the histological preparation of the fixed tissue.
Histochemical staining of the tissue sections for mast cells was achieved by
keeping with the manufacturer protocol, using naphthol-AS-D chloroacetate
esterase (kit obtained from Sigma).
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4.4

RESULTS:

4.4.1 Tumor response and granulocytes migration to the addition of
Cromolyn during 5-FU therapy
To determine tumor response to the effect of adding Cromolyn during the
weeks when 5-FU is not administered to ApcMin/+ mice. These animals underwent
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Figure 4.2: Tumor analysis from ApcMin/+mice subjected to therapy with no
recovery. a. .Intestinal sections stained with methylene blue from three mice in the
treatment groups with no recovery from the chemotherapy regimen. b. Tumor burden in
ApcMin/+mice subjected to therapy with no recovery. Tumor burden in mice treated with
5-FU or 5-FU/CR indicated a significant decrease in tumor burden as compared to the
PBS-treated group (p=0.015 and p= 0.007, respectively). Treatment with Cromolyn
alone did not reduce tumor burden. c. Number of tumors that are less than 1 mm in size
in mice treated with 5-FU, Cromolyn, or 5-FU and Cromolyn with no recovery. d.
Number of tumors that are greater than 1 mm in size in mice treated with 5-FU,
Cromolyn, or 5-FU and Cromolyn with recovery. Tumor size in mice treated with 5-FU
and 5-FU/CR were significantly smaller when compared to those in mice treated with
PBS (p=0.0094 and p=0.0020 respectively).

this alternative treatment schedule from six to ten weeks of age. PBS, 5-FU, and
Cromolyn groups were used as control groups. Tumor burden for the intestines
of these animals indicate that the addition of Cromolyn during the off weeks of 5-
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FU treatment does significantly reduce tumor number compared to the PBS
treated animals. In addition promising results show that tumor numbers in the 5FU/CR group is slightly lower than the animals that were subject to 5-FU alone
(Figure 4.2b). When scoring the tumors by size both 5-FU and 5-FU/CR groups
indeed inhibit regression of tumor development, for both these groups had less

PBS

5-FU

Cromolyn

5-FU/CR

10X

40X

Figure 4.3: Infiltration of mast cells and granulocytes in intestinal tissue from
ApcMin/+mice subjected to therapy with no recovery. a. Localization of mast cells
and granulocytes by histochemical staining of intestinal tissues from treated mice with
no recovery using naphthol-AS-D chloroacetate esterase. Mast cells and granulocytes
are highly abundant in the peripheral regions of tumors from mice treated with PBS, 5FU, and Cromolyn. Mast cells are not observed in tumors from mice treated with a
combination of 5-FU and Cromolyn. b. Quantification of mast cells and granulocytes in
tumor regions of treated mice without recovery after chemotherapy. There is significant
difference between treatment with 5-FU and 5-FU/CR (p=0.0192 and p=0.0135,
respectively) as compared to treatment with PBS.

number of tumors measure greater than 1mm compared to the PBS animals, yet
the 5-FU/CR treatment was slightly better than the 5-FU alone (Figure 4.2 d).
These results suggest that a synergetic response is occurring by administer
Cromolyn during the alternative weeks of 5-FU treatment. Conversely, in
analyzing the tumor response in the animals treated with Cromolyn alone we
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observe an increase in tumor burden as well as an increase of the tumors that
are greater than 1mm when comparing to all of the other treatment groups
(Figure 4.2). This data indicates the Cromolyn alone is not able to inhibit
regression or the multiplicity of tumor development or growth in ApcMin/+ mice.
Upon histochemical analysis, infiltration of granulocytes and mast cells into the
tumor occurs more frequently in the Cromolyn treated animals than the 5-FU or
5-FU/CR animals and appears to be similar to the PBS animal. This data suggest
that 5-FU is either prohibiting the maturation of these cells for which then
influencing these cells ability to infiltrate into the tumor or just influences the
infiltration of these cells into the tumor for the environment is alter by the
treatment, and therefore these cells are not recruited (Figure 4.3). The addition of
Cromolyn during 5-FU treatment demonstrated promising results, however, 5-FU
treatment alone as shown to be promising, however once treatment is ceased
tumor recurrence is problematic. Thus, we examine tumor response to
administering Cromolyn post 5-FU therapy.
4.4.2 Tumor response and granulocytes migration to the addition of
Cromolyn post 5-FU therapy
To determine tumor response to the effect of adding Cromolyn post 5-FU
therapy in ApcMin/+ mice. These animals underwent this treatment therapy from
six to fifteen weeks of age, for which the tenth up to the fifteenth week of age
represent the period of treatment recovery. PBS, 5-FU, and Cromolyn groups
were again used as control groups. Tumor burden for the intestines of these
animals indicate that the addition of Cromolyn post 5-FU treatment does
significantly reduces tumor number compared to both the PBS and 5-FU treated
117

animals (Figure 4.4b). Also from these result it is important to indicate that we did
not observe any significant difference when comparing the PBS with 5-FU
treated animals, indicating that rebound of tumor growth occurred during the
period of recovery. Thus, the addition of Cromolyn post 5-FU therapy further

Figure 4.4: Tumor analysis from ApcMin/+mice subjected to therapy with recovery.
a.Intestinal sections stained with methylene blue from three mice in the treatment
groups with recovery from the chemotherapy regimen. b. Tumor burden in ApcMin/+mice
subjected to therapy with recovery. Tumor burden in mice treated with 5-FU-CR-R
caused a significant decrease in tumor burden as compared to the PBS-treated group
(p=0.0009). There is a significant decrease in tumor burden in mice that were treated
with 5-FU and Cromolyn with recovery as compared to mice treated with 5-FU alone
and allowed to recover. The mice treated with Cromolyn alone did not show a
decrease in tumor burden.c. Tumor counts for which the size is less than 1mm for each
treatment groups for the recovery regimen. d. Tumor count sizes that is greater than
1mm for each treatment groups in the recovery regimen. Tumor sizes for groups 5-FU
and 5-FU-CR-R (p=0.0469 and p=0.0001 respectively) were significantly smaller when
compared to PBS tumor sizes.

suggests promising effects in inhibiting tumor growth. This implication is further
validated when tumor scoring of size is analyzed and results show that there is a
statistical reduction of the number of tumor, which are greater than 1mm in the
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intestines of animals treated with 5-FU and Cromolyn during the recovery period
in comparison to the PBS and 5-FU animals (Figure 4.4d). These results
indicates that a synergetic response does occurring by administer Cromolyn post
5-FU treatment, by assisting in the inhibition of tumor regression.
Again in opposition, animals treated with Cromolyn alone we observe an
increase in tumor burden as well as an increase of the tumors that are greater
than 1mm when comparing to all of the other treatment groups (Figure 4.4). This
data reiterates that Cromolyn alone is not able to inhibit regression or the

PBS-R

5-FU-R

5-FU-R+CR

CR-R+CR

10X

40X

Figure 4.5: Infiltration of mast cells and granulocytes in intestinal tissue from
ApcMin/+mice subjected to therapy with recovery. a. Localization of mast cells and
granulocytes by histochemical staining of intestinal tissues from treated mice with
recovery from therapy using naphthol-AS-D chloroacetate esterase. Mast cells and
granulocytes were highly abundant in the peripheral regions of the tumor.
b.
Quantification of mast cells and granulocytes in tumor regions of treated mice that were
allowed to recover from chemotherapy. There is a significant difference in mice treated
with the 5-FU-CR-R regimen as compared to mice treated with PBS (p=0.0041).

119

multiplicity of tumor development or growth in ApcMin/+ mice. In addition,
histochemical analysis, confirms more infiltration of granulocytes and mast cells
into the tumor of the Cromolyn group than the animals treated with PBS, 5-FU or
5-FU/CR. The increase influx of granulocytes seen only in the Cromolyn treated
animals suggests that Cromolyn is influencing either the maturation or function of
these particular cells (Figure 4.5). This is important to understand so that we may
better understand the synergetic response that is occurring when adding
Cromolyn post 5-FU treatment in ApcMin/+ mice.
4.4.3 Systemic response to the effects to Cromolyn treatment
To determine the influence of Cromolyn on granulocytes maturation and
function, collection of serum from mice prior and after treatment is analyze to
determine the systemic levels of various cytokines and chemokines by a
multiplex or an ELISA assays. The multiplex analysis allowed evaluation of many
cytokines and chemokines in one assay (data not shown); however, most
relevant are the results from the analysis of the granulocyte colony-stimulating
factor, which warned attention for it correlates with the previous observation of
increase infiltration of granulocyte in the tumor region of those mice treated with
only Cromolyn. Shown in figure 4.6a we observe higher systemic levels of GCSF only in mice subjected to Cromolyn compared to the other treatment
regimen. Implicating that Cromolyn is indirectly influence the maturation of bone
marrow cells into granulocytes by elevating the systemic levels of G-CSF. Yet, in
examining, the systemic histamine levels of each treatment group, results do not
show any significant difference (Figure 4.6b). Histamine levels do not appear to
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decrease from the addition of Cromolyn, suggesting either that mast cells are not
sufficiently inhibit by Cromolyn effects, or that other immune cells are
compensating for the lack of histamine released, due to mast cell inhibition by
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Figure 4.6: Serum levels of G-CSF and histamine. a. Serum levels of granulocyte
colony stimulating factor were measure by multi-plex assay. Concentration of G-CSF is
highly elevated in mice treated with CR-CR-R regimen. b. Serum levels of histamine in
mice subjected to chemotherapy followed by recovery. Serum samples were obtained
prior to treatment (pre-bleed, PB) and after treatment (final-bleed, FP). ELISA determined
levels of histamine in serum samples.

Cromolyn. The latter of the two explanations seem more plausible, for clear
Cromolyn is affecting other immune cells maturation and function as previous
described.

4.5

DISCUSSION:
The data suggests that administration of Cromolyn during recovery lessen

tumor multiplicity possibly by interfering with the regrowth of residual tumors for
the tumor sizes were significantly smaller in mice subjected to Cromolyn post 5FU therapy. However, even though these results are promising in sustaining
regression of the tumor development, there are hesitations in consider Cromolyn
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the appropriate drug choice for sustaining tumor regression. Solely evaluated
animals treated with Cromolyn alone, results show a significant increase of
tumors multiplicity and the inability of Cromolyn to inhibit the progression of tumor
development. In actuality, Cromolyn appear to encourage tumor genesis in the
ApcMin/+ mice model, for the tumors drastically larger and highly vascularized.
These results were alarming and contrary to previous studies that have indicated
that Cromolyn mitigates tumor progression (Soucek, Lawlor et al. 2007; Pittoni,
Tripodo et al. 2011). A plausible explanation for contradicting results is the
differences in mouse models and the type of cancer examine to evaluate the
effects of Cromolyn. Despite, the differences in results the data from this study is
insightful, such that Cromolyn, is consider a mast cells stabilizer; and by affecting
the function of mast cells we potentially influence the function of other immune
cells, thus causing a negative effect. This increase progression of tumor
development coincides with a study that demonstrates that the ablation of mast
cells in ApcMin/+ mice also results in the increase of tumor burden and size when
compared to littermates (Sinnamon, Carter et al. 2008). In addition, this particular
study observed that ablation of mast cells resulted in a significant decrease influx
of tumor infiltrating eosinophils and a slight increase of neutrophils. Theses
evidences can implicate that during tumor development mast cells exhibits
protective properties, by means of influencing the function or migration of other
immune cells into the tumor, to assist with the inhibition of tumor progression.
Therefore, in accordance with the result observed by the animals treated only
with Cromolyn, mast cells protective role of influencing other immune cells may
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be disrupted, resulting in deficiency regulation of immune cells and the high
infiltration of granulocytes cells within the tumor to compensate for the lack of
mast cell activity. This high influx of granulocytes can potentially be the
contributing factor to the expansion of tumor burden observed in the Cromolyn
only treated animals.
Indeed, we did not observe any statistically difference in systemic levels of
histamine for any of the treatment groups, thus unable to validate mast cell
inhibition. Nonetheless, we have no inclination to suggest that Cromolyn failed to
inhibit mast cells degranulation in this model, but incline to say that the inhibition
effects were not observed. For we only examined the level of systemic histamine
only at the beginning and end of any drug treatment. The longevity of Cromolyn’s
affect and the mechanism for which it inhibits mast cells is poorly understood. It
is state to inhibit mast cells by indirectly inhibiting the influx of chloride ion across
the cell membrane to assist with the activation of degranulation. The
generalization of Cromolyn effects can indeed influence the function of other cell
type if not all cell type. Several studies have observed Cromolyn’s effect on other
cell types, for instance, an in-vitro study showed that pre-incubation of human
neutrophils, monocytes, and eosinophil with Cromolyn resulted in inhibits the
activation of these cells in response to synthetic bacterial analogue (Kay, Walsh
et al. 1987). In addition, Cromolyn has been shown to inhibit the migration of
eosinophil (Bruijnzeel, Warringa et al. 1990). Another study shows Cromolyn
ability to inhibit the function of chloride channels on epithelial intestinal cell line
HT29 (Reinsprecht, Pecht et al. 1992). Thus, further studies need to be perform
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to determine the effect of Cromolyn on cells in the microenvironment to assess
its potential as a therapeutic agent that can be used synergistically with 5-FU to
enhance anti-tumor effects of prolong tumor recurrence post therapy.
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CHAPTER 5

SUMMARY AND FUTURE DIRECTIONS

The progression of cancer is a multi-step process, for which cells undergo
several mutations, and the development of colorectal cancer is no exception.
One of the many painstaking events of tumorigenesis has been underlining the
involvement and the function of the tumor microenvironment. The TME
comprised of non-neoplastic cells derived from the hematopoietic system; and
ironically, some of these non-neoplastic cells exhibits characteristics, which
promotes and assist with tumor development. This multifaceted interaction
between cancer cells and the non-neoplastic cells within the TME influences both
the progression of the tumor, and how the tumor responds to chemotherapy.
Hence, the efficacies of chemotherapies are reliant on the responsiveness of
both neoplastic and non-neoplastic cells.
For decades, the focus of chemotherapy drugs was design to target
neoplastic cells, for tumors was perceived to be a composition of highly
proliferative neoplastic cells. A prevalent drug used in the past and present to
treat colorectal cancer and other cancers is 5-Fluorouracil. This drug has been
effective for it inhibits the catalytic function of the enzyme Thymidylate Synthase.
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TS is highly expressed in cells that are proliferating, and neoplastic cells are
highly proliferative, thus the efficacy of 5-FU is promising in treating cancer.
However, the pitfalls of using this drug are its systemic cytotoxic side effects, due
to its lack of specificity; and the reoccurrence of cancer after treatment. Thus, to
circumvent these shortcomings we developed and examined the effects of two
therapeutic strategies that would target both neoplastic and non-neoplastic cells
in the TME to enhance 5-FU effectiveness and reduce its cytotoxicity.
The first therapeutic strategy involved lessening the levels of TS in
BMDCs that infiltrates and establishes the TME. The postulation of this
therapeutic strategy evolved from

previous studies that demonstrated

reprogramming BMDCs to expressed E.coli TS, a resistant phenotype decreased
the efficacy of 5-FU in tumors. The implications from these studies suggested
that reprogramming the protein expression in cells influences response to
chemotherapy. Conversely, reprogramming cells to express lesser levels of TS
should enhance 5-FU efficacy. To accomplish reduction of TS protein, RNA
interference technologies were used to inhibit the translation of TS mRNA, and
results showed an increase of cellular sensitivity to 5-FU. However, troublesome
results were observed in our first attempts to used genetic modified BMDCs.
These troublesome results stress the importance of using an appropriate RNAi
model system, especially if this particular therapy becomes applicable for treating
cancer in humans.
Eventually we obtain an appropriate RNAi vector system, which permitted
us to examine the effects of modulated BMDCs in the tumor of the subcutaneous
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CT26 cancer mouse model. In addition, the identity of a non-cytotoxic RNAi
vector system we confirm that the OPN promoter has inducible characteristics
that are only functional in pro-inflammatory environments, such as the TME.
Additionally, the OPN promoter has the aptitude to drive the expression of an
RNAi sequence against TS to establish enhance sensitivity to 5-FU therapy.
Although we obtain the essential components to establish tumor specific chemosensitivity our results were not significant, and therefore we are unable to
confidently conclude that this therapeutic application is beneficial. Nevertheless,
with additional studies describe in Chapter 4 are performed this therapeutic
strategy could be utilized to modulate the expression of various proteins in
BMDCs which infiltrates the tumor. Thus, essential our studies are just the
beginning in providing insight to improve this therapeutic strategy. Future studies
from this therapeutic strategy could involve reducing expression of VEGF, TGFbeta, HGF and other pro-tumorigenic proteins, or at best increase the expression
of anti-tumorigenic proteins. After more scrutiny and investigation, the ability to
modulate the protein expression of BMDCs that infiltrates the TME could disrupt
pro-tumorigenic functionality of these cells, and provide several avenues of
therapy.
On the other hand, incorporating additional pharmacological drugs which
targets specific BMDCS with current therapies can also potential beneficial in
reducing tumor growth and reducing reoccurrence after therapy. In our case, the
administration of Cromolyn to inhibit the function of mast cell in conjunction with
5-FU therapy did indeed reduce tumor growth and reoccurrence. However, not
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fully understand the mechanistic effect of Cromolyn we were unable to conclude
the longevity of therapeutic application would be beneficial. Thus, with additional
studies examining the effects of Cromolyn on other BMDCs will be beneficial in
determine if this l drug is appropriate to use in combination with 5-FU to prevent
reoccurrence of tumors. Additionally, the kinetics of Cromolyn effects within the
tumor needs to be investigated to determine if prolong usage of this drug is
beneficial in combination with 5-FU therapy.
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